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Summary
Background Measurement of changes in health across locations is useful to compare and contrast changing 
epidemiological patterns against health system performance and identify specific needs for resource allocation in 
research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and 
Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population 
health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track 
trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI).
Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, 
cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories 
from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each 
location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability 
per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric 
mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate.
Findings The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years 
(95% uncertainty interval 71·9–78·6) for females and 72·0 years (68·8–75·1) for males. The lowest for females was 
in the Central African Republic (45·6 years [42·0–49·5]) and for males was in Lesotho (41·5 years [39·0–44·0]). From 
1990 to 2016, global HALE increased by an average of 6·24 years (5·97–6·48) for both sexes combined. Global HALE 
increased by 6·04 years (5·74–6·27) for males and 6·49 years (6·08–6·77) for females, whereas HALE at age 65 years 
increased by 1·78 years (1·61–1·93) for males and 1·96 years (1·69–2·13) for females. Total global DALYs remained 
largely unchanged from 1990 to 2016 (–2·3% [–5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and 
nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The 
exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were 
Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic 
heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs 
and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY 
burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. 
Interpretation At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that 
many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative 
years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression 
of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace 
with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and 
their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. 
Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform 
health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for 
health, including financial and research investments for all countries, regardless of their level of sociodemographic 
development. The presence of countries that substantially outperform others suggests the need for increased scrutiny 
for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming 
countries suggests the need for devotion of extra attention to health systems that need more robust support.
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Introduction
Objective measurement of population health is a fun­
damental requirement of good governance that allows 
international, regional, national, and local actors to frame 
evidence­based policy informed by past trends and current 
performance of health systems.1–4 Summary measures of 
population health include techniques that measure the 
overall burden of health loss due to fatal and non­fatal 
diseases, as well as measures of expected fatal and non­
fatal disease burden based on Socio­demographic Index 
(SDI).5 The disability­adjusted life­year (DALY) measures 
health loss due to both fatal and non­fatal disease burden. 
DALYs are the sum of the years of life lost (YLLs) due to 
premature mortality and years of life lived with disability 
(YLDs).6 The YLL is based on remaining life expectancy 
when compared with a reference standard life table at age 
of death,7 and the YLD is calculated by multiplying the 
prevalence of a disease or injury and its main disabling 
outcomes by its weighted level of severity.6,8 One DALY 
represents 1 year of healthy life lost. Examination of levels 
and trends of DALYs facilitates quick comparison between 
different diseases and injuries. Conversely, healthy life 
expectancy (HALE), a metric based on methods by 
Sullivan,9 provides a single summary measure of popu­
lation health across all causes combined by weighting 
years lived with a measure of functional health loss before 
death and is the most comprehensive among competing 
expectancy metrics.1–4 Together, DALYs and HALE enable 
comparisons of the magnitude of functional health loss 
across societies due to diseases, injuries, and risk factors, 
against which provisioning and performance of health 
systems can be calibrated.4
Research in context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
2015 (GBD 2015) provided disability-adjusted 
life-year (DALY) estimates for 315 diseases and injuries for 
195 countries and territories, including subnational 
assessments for 11 countries and, thus, for a total of 
519 locations, from 1990 to 2015. GBD 2015 also introduced 
analyses of DALYs and healthy life expectancy (HALE) in 
relation to the Socio-demographic Index (SDI). Only the WHO 
Global Health Estimates has published updated estimates of 
DALYs, and these estimates were heavily reliant on GBD 2015 
results.
Added value of this study
This study, the Global Burden of Diseases, Injuries, and Risk 
Factors Study 2016 (GBD 2016), updates and improves the 
first of the annual Global Burden of Disease iterations, 
GBD 2015. GBD 2016 is, to our knowledge, the only peer-
reviewed, Guidelines for Accurate and Transparent Health 
Estimates Reporting-compliant, comprehensive, and annual 
assessment of DALYs and HALE by age group, sex, cause, and 
location, analysed consistently from 1990 to 2016. The 
improved approaches to the analysis and refinements in data 
(gap fills, updates, and revisions), as well as the widening of 
scope by cause, location, age, and time are all relevant to this 
study. The summary population health metrics of DALYs and 
HALE synthesise the cumulative effect of all of these 
improvements, the most notable of which are as follows. First, 
we added substantial location-years of cause-specific mortality 
data and non-fatal data for GBD 2016. The added data 
progressively fill gaps in the period of estimation, most 
substantially for India. Second, many analytical methods have 
been improved, such as improvement of mortality to incidence 
ratios for cancers to better reflect lower survival than in 
GBD 2015 and for non-fatal tuberculosis to better reflect 
higher incidence in low-income and middle-income countries 
based on SDI. Third, we included new subnational assessments 
for Indonesia at the provincial level and further disaggregated 
subnational estimation in England to the local government 
area level. Fourth, we refined our estimation of age-specific 
outcomes for ages 80 years and older into 5 year groups 
extending to age 95 years and older to better account for 
disease burden in elderly populations than in GBD 2015. Fifth, 
we estimated DALYs for several additional causes for the first 
time. Sixth, we improved our analysis of the epidemiological 
transition as a function of SDI, which allowed for a more 
nuanced interpretation of global health trends against the 
sociodemographic development spectrum than in GBD 2015. 
Finally, we used these analyses to identify the exemplar 
countries that exceeded population health summary metric 
expectations relative to their SDI position alone. The GBD 2016 
iteration supersedes all previous GBD studies of DALYs and 
HALE and re-estimates these measures for the complete time 
series from 1990 to 2016. We focus on new methods and 
approaches since GBD 2015 and highlight nations that 
overperformed or underperformed on the basis of what would 
be expected on the basis of their SDI. 
Implications of all the available evidence
The epidemiological transition continues apace globally, with 
a shift from DALYs attributable to communicable, maternal, 
neonatal, and nutritional diseases to those attributable to 
non-communicable diseases. This progression is concomitant 
with improvements in SDI and thus improvements in 
education, fertility rates, and economic status. A more 
detailed analysis than in this study of the epidemiological 
changes that have occurred in countries that have consistently 
exceeded expectations could provide improved insights into 
good practice in public health policy, which might be 
emulated elsewhere. A similarly detailed appraisal of countries 
that are lagging in DALYs and HALE relative to expectations 
on the level of SDI alone will help identify countries in most 
need of domestic and international attention across the 
development continuum.
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As the second in a series7,8,10,11 of now annual updates, 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study 2016 (GBD 2016) is the most comprehensive and 
current source of summary health metrics. The Global 
Burden of Disease (GBD) is based on development of the 
largest available database of health outcomes, risk factor 
exposure, intervention coverage, and sociodemographic 
factors related to health. We applied analytical techniques 
to reduce data biases and support comparability, propa­
gated the uncertainty in these estimates, and provided 
insights at the highest temporal and spatial resolution 
afforded by the data.
The purpose of this study is to present the results of 
GBD 2016 for DALYs and HALE, building on updated 
estimates of mortality, causes of death, and non­fatal 
health loss7,10 to identify nations with notable variation in 
health performance from that expected on the basis of 
SDI. Approaches to the analysis have been previously 
described.2–4,12 GBD 2016 improvements include addition 
of newly available retrospective data, refined analytical 
methods (such as improvement to mortality to incidence 
ratios [MIRs] for cancers to better reflect lower survival in 
low­income and middle­income countries based on SDI), 
new subnational estimation for England and Indonesia, 
disaggregation of certain cause groupings to capture 
greater detail, and expansion of older age groups to 




We used the results of GBD 2016 to evaluate trends in 
epidemiological patterns and health performance on a 
global, regional, national, and subnational scale using 
DALYs and HALE as summary measures of changes in 
health states. Greater detail than presented in this section 
for methods used to estimate DALYs and HALE, 
including analytic approaches for assessment of relative 
morbidity and mortality from individual diseases and 
injuries, is provided in related publications in this 
series8,10 and the appendix.
This analysis follows the Guidelines for Accurate and 
Transparent Health Estimates Reporting,13,14 which include 
recommendations on documentation of data sources, 
estimation methods, and statistical analysis. We did 
analyses using Python version 2.7.12 and 2.7.3, Stata 
version 13.1, and R version 3.2.2. For more information on 
Guidelines for Accurate and Transparent Health Estimates 
Reporting compliance, please refer to the appendix 
(pp 13–15). Additionally, interactive online tools are 
available to explore GBD 2016 data sources in detail. 
Cause­specific estimation for GBD 2016 covers the years 
1990–2016. For a subset of analyses, we focus on the last 
decade, from 2006 to 2016, to address current policy 
priorities. The GBD 2016 results for all years and by 
location can be explored further with dynamic data 
visualisations.
Cause and location hierarchies
In the GBD 2016 study, causes of mortality and morbidity 
are structured with use of a four­level classification 
hierarchy to produce levels that are mutually exclusive and 
collectively exhaustive. GBD 2016 estimates 333 causes of 
DALYs, 68 of which are a source of disability but not a 
cause of death (such as trachoma, hookworm, and low 
back and neck pain) and five of which are causes of death 
but not sources of morbidity (sudden infant death 
syndrome, aortic aneurysm, late maternal deaths, indirect 
maternal deaths, and maternal deaths aggravated by 
HIV/AIDS). Within each level of the hierarchy, the 
number of collectively exhaustive and mutually exclusive 
fatal and non­fatal causes for which the GBD study 
estimates is three at Level 1, 21 at Level 2, 168 at Level 3, 
and 276 at Level 4. The full GBD cause hierarchy, including 
corresponding International Classification of Diseases 
(ICD)­9 and ICD­10 codes, is detailed in GBD 2016 
publications on cause­specific mortality10 and non­fatal 
health outcomes,8 with cause­specific methods detailed in 
the corresponding appendices.
The GBD study is organised by a geographical hierarchy 
of seven super­regions containing 21 regions, with 
195 countries and territories nested within those regions.12 
GBD 2016 included new subnational assessments for 
Indonesia by province and for England by local govern­
ment area. In this study, we present subnational data for 
the five countries with a population greater than 
200 million people in 2016: Brazil, China, India, Indonesia, 
and the USA.
Estimation of mortality and non-fatal health loss
To estimate all­cause and cause­specific mortality, the 
GBD study first systematically addressed known data 
challenges—such as variation in coding of causes or 
age group reporting, misclassification of deaths from 
HIV/AIDS, or methods for incorporation of population­
based cancer registry data—using standardised methods 
described in detail in the GBD 2016 mortality7 and causes 
of death10 publications. As noted in other GBD 
publications, each death is attributed to a single underlying 
cause in accordance with the ICD. We take steps to 
standardise cause of death data to address the small 
fraction of deaths that are not assigned an age or sex, 
deaths assigned to broad age groups that are not 5 year 
age groups, and various revisions and national variants of 
the ICD. Additionally, we identify and redistribute deaths 
assigned to ICD codes that cannot be underlying causes of 
death, are intermediate causes of death rather than the 
underlying causes, or lack specificity in coding.10 We 
estimated cause­specific mortality using standardised 
modelling processes—most commonly, the Cause of 
Death Ensemble model, which uses covariate selection 
and out­of­sample validity analyses and generates 
estimates for each location­year, age, and sex.10 Additional 
detail, including model specifications and data availability 
for each cause­specific model, can be found in the 
See Online for appendix
For the online tools see 
http://ghdx.healthdata.org
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appendix of the GBD 2016 mortality7 and causes of death10 
publications. We used the all­cause mortality estimates to 
establish a reference life table from the lowest death rates 
for each age group among locations with total populations 
greater than 5 million.7 From this reference life table, we 
multiplied life expectancy at the age of death by cause­
specific deaths to calculate cause­specific YLLs. We then 
used the GBD world population age standard to calculate 
age­standardised rates for deaths and YLLs.7 The GBD 
world population age standard and the standard life 
expectancies are available in the appendix of the GBD 2016 
mortality publication.7
Changes implemented since the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) 
for cause­specific mortality include incorporation of 
substantial sources of new mortality data; important model 
improvements for HIV, malaria, tuberculosis, injuries, 
diabetes, and cancers; disaggregation of specific causes 
into subgroupings to provide additional detail (the 
following were all estimated separately for the first time: 
alcoholic cardiomyopathy; urogenital, musculoskeletal, 
and digestive congenital anomalies; Zika virus disease; 
Guinea worm disease; self­harm by firearm; sexual 
violence; myocarditis; and the following types of tuberc­
ulosis: extensively drug­resistant tuberculosis, multidrug­
resistant tuberculosis without extensive drug resistance, 
drug­susceptible tuberculosis, extensively drug­resistant 
HIV/AIDS­tuberculosis, multidrug­resis tant HIV/AIDS­
tuberculosis without extensive drug resistance, and 
drug­susceptible HIV/AIDS­tuberculosis); modelling of 
anti retroviral therapy (ART) coverage for each location­
year by CD4­positive cell count at initiation; breakdown of 
terminal age groups from 80 years and older to 80–84 years, 
85–89 years, 90–94 years, and 95 years and older; expansion 
of the GBD location hierarchy; and changes in the 
calculation of SDI.10 The database for GBD 2016 now 
includes data for the 333 causes estimated for DALYs and 
new subnational units for Indonesia (n=34) and England 
(n=150). For GBD 2016, we included substantial amounts 
of additional data sources from new studies and our 
network of collaborators; details of the types of data added 
can be found in the GBD 2016 cause of death10 and non­
fatal8 publications. Additionally, research teams did 
systematic reviews to incorporate literature data into fatal 
and non­fatal models. Further details on search strings are 
available in the GBD 2016 non­fatal8 and cause of death10 
publication appendices. The Registrar General of India 
provided improved verbal autopsy data collected through 
their Sample Registration System, enabling a more 
detailed and thorough analysis of subnational data for 
India than in GBD 2015. The methods for constructing the 
SDI, initially developed for GBD 2015,15 were revised for 
GBD 2016 to account for expansion in the number of 
subnational estimates and the effect of a growing time 
period of estimation given fixed limits for index 
components.10 The components of SDI—total fertility rate 
(TFR), educational attainment in the population aged older 
than 15 years, and lag­distributed income (LDI)—are based 
on new systematic assessments of educational attainment, 
LDI, and fertility, and each component is scaled relative to 
maximum effect on health outcomes.10
In most cases, we estimated non­fatal health loss using 
the Bayesian meta­regression tool DisMod­MR 2.1 to 
synthesise variable data sources to produce internally 
consistent estimates of incidence, prevalence, remission, 
and excess mortality.16 Cause­specific data availability 
and epidemiological characteristics required additional 
analytical techniques in some cases (details are available 
in the appendix of the GBD 2016 non­fatal publication8); 
these causes include many neglected tropical diseases 
(NTDs) such as dengue, as well as injuries, malaria, and 
HIV/AIDS.17,18
We estimated each non­fatal sequela separately and 
assessed the occurrence of comorbidity in each age group, 
sex, location, and year separately using a microsimulation 
framework. We distributed disability estimated for 
comorbid conditions to each contributing cause during the 
comorbidity estimation process. Although the distribution 
of sequelae—and therefore the severity and cumulative 
disability per case of a condition—can be different by age, 
sex, location, and year, previous studies have found that 
disability weights do not substantially vary across locations, 
income, or levels of educational attainment.19,20 In the GBD 
study, disability weights were based on population surveys 
with 60 890 respondents and held invariant between 
locations and over time.20 Additional details, including 
model specifications and data availability for each cause­
specific model and development of disability weights by 
cause and their use in the estimation of non­fatal health 
loss, are available in the appendix of the GBD 2016 non­
fatal publication.8
For non­fatal estimation, several methodological 
changes were made for GBD 2016. New data for the main 
causes of YLDs were identified through our collaboration 
with the Indian Council of Medical Research and the 
Public Health Foundation of India. For particular risk 
factors and diseases, the volume of available data 
increased substantially, such as child growth failure 
(stunting, wasting, or underweight), anaemia, congenital 
anomalies, schistosomiasis, intestinal helminths, and 
lymphatic filariasis. We have improved our analysis of 
total admissions per person by country, year, age, and 
sex, which facilitated incorporation of additional hospital 
data sources that were previously excluded because of 
incomplete knowledge of catchment population size. We 
extended our analyses of linked USA medical claims data 
to impute age­specific and sex­specific ratios for multiple 
admissions per illness episode, ICD code appearance in 
the non­primary position, and inpatient versus outpatient 
use.8 We applied each of the three ratios sequentially to 
non­linked hospital inpatient data from elsewhere that 
only had a single ICD code per visit to adjust prevalence 
and incidence data. We have incorporated more 
predictive covariates into our non­fatal disease models to 
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better predict variation in disease levels rather than 
measurement error as the source of variation, and we 
improved our analysis of the MIRs for cancers, resulting 
in considerably higher ratios in lower SDI quintiles and 
thus substantially lower YLD estimates for cancer.
Estimation of DALYs, HALE, and corresponding 
uncertainty
We calculated DALYs as the sum of YLLs and YLDs for 
each cause, location, age group, sex, and year.8,10 The same 
estimates of YLDs per person for each location, age, sex, 
and year from 1990 to 2016 are used to establish HALE by 
age group within abridged multiple­decrement life tables 
with use of methods developed by Sullivan.9
For all results, we report 95% uncertainty intervals (UIs) 
derived from 1000 draws from the posterior distribution of 
each step in the estimation process. Unlike confidence 
intervals, UIs capture uncertainty from multiple modelling 
steps, as well as from sources such as model estimation 
and model specification, rather than from sampling error 
alone. Uncertainty associated with estimation of mortality 
and YLLs reflects sample sizes of data sources, adjustment 
and standardisation methods applied to data, parameter 
uncertainty in model estimation, and uncertainty within 
all­cause and cause­specific mortality models. For esti­
mation of prevalence, incidence, and YLDs, UIs incor­
porated variability from sample sizes within data sources, 
adjustments to data to account for non­reference def­
initions, parameter uncertainty in model estimation, and 
uncertainty associated with establishment of disability 
weights. Because direct information about the correlation 
between uncertainty in YLLs and YLDs was scarce, we 
assumed that uncertainty in age­specific YLDs was 
independent of age­specific YLLs or death rates.
Epidemiological transition and relationship between 
DALYs, HALE, and SDI
For GBD 2016, the composite indicator of SDI was 
again based on the geometric mean of three measures—
LDI per person, average years of schooling among 
populations aged 15 years or older, and TFR—but the 
analysis was strengthened in three important ways.10 
First, we substantially revised estimates of education, 
adding new data and improved methods for subnational 
locations. Second, instead of using estimates of TFR 
from the UN Population Division, we systematically 
reviewed, extracted, and analysed fertility data from all 
available locations to derive a time series of TFR for 
each national and subnational GBD location.7 Third, 
rather than rescaling SDI on the basis of the full range 
of observed values within the time series, we developed 
a fixed scale for GBD 2016; details on development of 
this fixed scale are available in the GBD 2016 mortality 
publication.7 We examined the average relationship 
between DALYs, HALE, and SDI using a Gaussian 
process regression model; we used these regressions to 
estimate expected values of these summary measures 
at each level of SDI. Additional detail on SDI calculation 
and location­specific SDI values are available in the 
appendix of the GBD 2016 mortality publication.7
Data sharing
The statistical code used in the entire process is available 
through an online repository. 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
Global levels of and trends for DALYs and HALE
The total number of all­age DALYs in 2016 was 
2·39 billion (95% UI 2·18 billion to 2·63 billion). Total 
all­age DALY counts for CMNN causes fell by 40·1% 
(37·4–42·7) from 1·11 billion (1·07 billion to 1·16 billion) 
in 1990 to 668 million (632 million to 708 million) in 
2016, whereas total all­age DALY counts from NCDs 
increased by 36·6% from 1·07 billion (958 million to 
1·20 billion) in 1990 to 1·47 billion (1·30 billion to 
1·66 billion) in 2016 (table 1). Total DALYs from injuries 
decreased by 1·6% (–3·8 to 6·2) from 260 million 
(243 million to 277 million) in 1990 to 255 million 
(236 million to 281 million) in 2016. Age groups older 
than 80 years had 149 million (139 million to 159 million) 
all­age DALYs in 2016 compared with 75·1 million 
(71·1 million to 79·5 million) in 1990, with increases 
across all SDI quintiles. Of these, 87·8% were due to 
NCDs in 2016 compared with 86·8% in 1990. 
From 1990 to 2016, global HALE at birth increased 
from 56·9 years to 63·1 years, with 160 of 195 locations 
registering significant improvements. Global HALE 
increased by an average of 6·24 years (95% UI 
5·97–6·48) for both sexes combined. Globally, HALE at 
birth increased from 55·38 years (53·27–57·31) in 1990 
to 61·42 years (59·01–63·58) in 2016 for males and from 
58·42 years (55·80–60·77) to 64·91 years (61·88–67·54) 
for females, rising 6·04 years (5·74–6·27) for males and 
6·49 years (6·08–6·77) for females (tables 2 and 3). The 
total number of years of functional health lost (life 
expectancy minus HALE) increased from 1990 to 2016, 
from 8·22 years to 9·34 years. The gap between life 
expectancy at birth and HALE, which represents years 
of functional health lost, grew between 1990 and 2016 
from 7·32 years (life expectancy 62·70 [62·42–62·99] vs 
HALE 55·38 [53·27–57·31]) to 8·37 years (69·79 
[69·29–70·22] vs 61·42 [59·01–63·58]) for males and 
from 9·15 years (67·57 [67·33–67·77] vs 58·42 
[55·80–60·77]) to 10·42 years (75·33 [74·95–75·64] vs 
64·91 [61·88–67·54]) for females. Globally, in 2016, life 
expectancy at age 65 years was 18·57 years (18·37–18·72) 
for females and 15·72 years (15·61–15·83) for males, 
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whereas HALE was 13·88 years (12·57–15·02) for 
females and 11·87 years (10·83–12·80) for males. HALE 
increased by 1·96 years (1·69–2·13) from 11·92 
(10·88–12·89) in 1990 for females and by 1·78 years 
(1·61–1·93) from 10·09 years (9·22–10·87) for males.
Global trends for all­age DALYs and age­standardised 
DALY rates for Level 1 causes by SDI quintile are shown in 
figure 1. Trends in total DALYs, which show the absolute 
burden at each SDI quintile, are shown in figure 1A. The 
figure highlights the large burden and subsequent declines 
in low­middle­SDI (decreased by 44·5% [95% UI 
41·3–47·6]) and middle­SDI (decreased by 56·2% 
[53·6–59·0]) locations for CMNN DALYs from 1990 to 2016, 
offset by large increases for NCD DALYs over the same 
time period in low­middle SDI (increased by 54·4% 
[47·9–60·8]) and middle­SDI (increased by 36·5% 
[39·9–32·8]) locations. Progress has been made in low­SDI 
countries for CMNN DALYs, which decreased by 20·7% 
(16·8–24·7) since 2006. At all levels of SDI, total NCD 
DALYs have increased since 1990. Trends in age­
standardised rates—which account for both population 
size and age structure—emphasise the reduction in the 
contribution of CMNN causes to DALYs, both over time 
and with increasing SDI (figure 1B). These rapid decreases 
in age­standardised rates were fastest at low SDI, where 
age­standardised DALY rates from CMNN causes decreased 
by 51·5% (49·0–54·1) between 1990 and 2016 to be on par 
with age­standardised DALY rates for NCDs in 2016. At 
low­middle SDI, age­standardised CMNN DALY rates were 
more than double those for NCDs in 1990 (31·7 thousand 
[30·3 thousand to 33·3 thousand] per 100 000), but 
decreased to 14·1 thousand (13·2 thousand to 15·1 thousand) 
per 100 000 in 2016. At all other levels of SDI, age­
standardised DALY rates for CMNN causes were lower 
than those for NCDs and lower than those of injuries in the 
high­SDI quintile. Reductions in age­standardised rates for 
NCDs occurred across all levels of SDI between 1990 and 
2016, a trend that was also evident, albeit less strongly, for 
age­standardised DALY rates from injuries.
Global causes of DALYs
Age­standardised DALY rates for all causes decreased by 
30·5% (95% UI 28·6–32·6) between 1990 and 2016 
(appendix pp 49–62). In 2016, CMNN causes accounted 
for 28·0% (26·4–29·7) of global DALYs, NCDs 
contributed 61·4% (59·4–63·2), and injuries contributed 
10·7% (10·1–11·3; appendix pp 35–48). From 2006 to 
2016, CMNN causes decreased by 31·9% (29·7–34·2), 
with 48 Level 4 CMNN causes experiencing decreases in 
age­standardised DALY rates of greater than 20% 
(table 1). Decreases were greater than 70% for 
three infectious diseases: Guinea worm disease 
(decreased by 99·6% [99·5–99·7]), human African 
trypanosomiasis (decreased by 78·2% [68·8–84·6]), and 
measles (decreased by 73·6% [68·8–77·8]). By contrast 
with the overall trend of decreasing DALYs, a subset of 
Level 4 CMNN causes had increases in age­standardised 
DALY rates, including dengue (50·5% [24·7–97·7]) and 
cutaneous and mucocutaneous leishmaniasis (12·5% 
[1·7–26·1]). Overall, total all­age DALYs attributable to 
maternal disorders decreased by 23·9% (17·4–29·3) 
between 2006 and 2016 and by 30·4% (24·4–35·4) in 
terms of age­standardised DALY rates. As a cause group, 
neonatal disorders decreased by 22·8% (18·9–26·8) in 
all­age DALYs and 23·1% (19·2–27·0) in terms of age­
standardised DALY rates over the same time period; 
however, this decrease was not significant for neonatal 
sepsis. Total DALYs from the London Declaration NTDs 
was 9·0 million (5·3 million to 14·5 million) in 2016.
In 2016, the leading Level 3 causes of total DALYs 
among NCDs included ischaemic heart disease 
(175 million [95% UI 170 million to 180 million] DALYs), 
cerebrovascular disease (116 million [111 million to 
121 million]), and low back and neck pain (87 million 
[61 million to 114 million]), comprising 16·1% 
(13·99–17·67) of all DALYs (table 1). Among chronic 
respiratory diseases, all causes, with the exception of 
interstitial lung disease, pulmonary sarcoidosis, and 
other chronic respiratory diseases, decreased in age­
standardised DALY rates between 2006 and 2016, whereas 
total all­age DALY counts increased from 2006 to 2016 for 
all chronic respiratory diseases, with the exception of 
silicosis. Cirrhosis and other chronic liver diseases had a 
mean change of 7·6% (2·5–13·7) from 2006 to 2016 in 
total all­age DALY counts, but had a mean decrease in 
age­standardised DALY rates of 12·0% (7·2–16·1) over the 
same period. Age­standardised DALY rates of digestive 
diseases decreased from 2006 to 2016, with a mean 
percentage decrease of 13·6% (10·8–16·4); however, all­
age DALY counts for digestive diseases increased by 4·1% 
(0·4–7·7) over the same period. Total DALYs associated 
with most neurological disorders increased from 
2006 to 2016, with Alzheimer’s disease and other de­
mentias (increase of 37·5% [35·3–39·7]) and Parkinson’s 
disease (increase of 35·6% [32·9–38·2]) increasing by 
more than 30% each. Between 2006 and 2016, various 
NCDs significantly increased in terms of both total 
burden and age­standardised DALY rates. Several mental 
and substance use disorders followed this pattern, 
including eating disorders (age­standardised DALY rates 
increased by 8·9% [7·6–10·1]) and bipolar disorder 
(increased by 0·8% [0·2–1·4]). Diabetes (all­age DALY 
count increased by 24·4% [22·7–26·2]) and chronic 
kidney disease (increased by 20·0% [17·4–22·7]) both also 
increased in all­age DALY counts, as did musculoskeletal 
disorders (increased by 19·6% [18·5–20·8]).
Percentage change in age­standardised DALY rates of 
unintentional injuries (decreased by 15·1% [95% UI 
12·2–18·0]), road injuries (decreased by 14·7% [12·8–16·8]), 
and transport injuries (decreased by 14·3% [12·3–16·4]) 
each decreased substantially between 2006 and 2016 
(table 1). Among unintentional injuries, drowning had the 
largest reduction in both all­age DALY burden (26·6% 
[20·1–30·1]) and age­standardised DALY rates (32·1% 
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All causes 2 448 430·5 
(2 305 218·2 to 
2 608 339·5)
2 490 698·9 
(2 308 527·1 
to 
2 689 861·1)
2 391 258·0 









(45 385·4 to 
51 762·0)
40 485·1 
(37 556·0 to 
43 679·3)
33 641·0 









neonatal, and nutritional 
diseases
1 114 176·6 
(1 073 948·8 to 
1 156 050·2)
918 804·8 
(885 242·1 to 
959 452·3)
667 823·7 









(17 386·0 to 
18 790·5)
13 801·1 














(79 728·6 to 
89 558·0)
159 063·9 
(152 851·5 to 
165 139·0)
101 133·3 























Tuberculosis 68 029·7 
(64 153·4 to 
73 066·3)
56 881·5 
(54 312·6 to 
59 442·6)
43 557·9 


























(63 730·5 to 
72 611·6)
51 760·2 
(49 194·0 to 
54 289·2)
39 869·8 
















































































·· ·· ·· ·· ·· ·· ·· ·· ·· ··
HIV/AIDS 16 154·8 
(14 497·1 to 
18 106·5)
102 182·3 
(96 751·1 to 
107 544·2)
57 575·4 






















































































































(67 021·8 to 
86 026·2)
44 814·9 




























(522 551·7 to 
600 325·4)
337 062·8 
(317 957·5 to 
359 176·2)
229 961·4 























Diarrhoeal diseases 175 168·6 
(150 592·6 to 
201 351·3)
113 944·8 
(99 183·9 to 
135 659·8)
74 414·6 
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(182 794·4 to 
220 607·6)
131 015·4 
(121 489·8 to 
139 228·6)
91 844·6 





















































































Meningitis 30 239·3 
(23 939·3 to 
34 552·6)
24 957·4 
(21 655·0 to 
28 764·2)
21 865·9 















































































































































































































































Tetanus 24 893·6 





























Measles 76 350·8 
































































(71 756·4 to 
103 455·7)
99 229·2 
(85 820·3 to 
113 978·1)
74 995·1 























Malaria 60 389·3 
(46 548·2 to 
74 912·5)
77 253·7 
(64 810·3 to 
91 256·8)
56 201·2 
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 (24·7 to 
97·7)*




















































































































































































































































Ebola virus disease ·· ·· 0·3 
(0·2 to 
1·1)
·· ·· ·· ·· ·· ·· ··
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Zika virus disease ·· ·· 5·1 
(3·4–8·0)
·· ·· ·· ·· 0·1 
(0·0–0·1)
·· ··





















































Maternal disorders 21 597·1 
(20 063·6 to 
22 834·1)
18 093·0 
(16 785·8 to 
19 171·8)
13 763·0 


















































































































































































































































































































Neonatal disorders 261 357·2 
(248 875·2 to 
282 758·2)
211 984·8 
(203 477·1 to 
221 317·2)
163 569·7 























Neonatal preterm birth 
complications
112 767·2 
(105 488·9 to 
124 122·5)
81 159·7 
(76 378·0 to 
89 409·0)
62 031·6 
























due to birth asphyxia, and 
trauma
68 251·9 
(61 749·3 to 
76 860·5)
60 334·8 
(55 822·8 to 
65 138·9)
47 031·7 























Neonatal sepsis and 
other neonatal infections
24 573·0 
(18 972·5 to 
31 156·6)
25 874·0 
(21 266·6 to 
32 360·3)
23 675·8 























Haemolytic disease and 
other neonatal jaundice
12 277·3 





























Other neonatal disorders 43 487·8 
(37 402·4 to 
50 951·9)
36 620·3 
(33 314·2 to 
40 250·5)
25 917·7 
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(Continued from previous page)
Nutritional deficiencies 69 823·3 
(57 049·4 to 
85 126·9)
64 648·9 
(51 489·2 to 
80 980·6)
60 936·1  


























(29 589·9 to 
41 569·5)
26 417·6 
(23 896·5 to 
29 406·0)
20 718·9 



















































































Iron-deficiency anaemia 27 097·5 
(18 018·7 to 
38 749·1)
32 422·9 
(21 535·8 to 
46 668·3)
34 841·8 
























































maternal, neonatal, and 
nutritional diseases
32 531·7 
(25 112·3 to 
42 021·4)
28 722·2 
(22 674·6 to 
36 833·4)
23 465·1 
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1 074 539·5 
(957 634·8 to 
1 197 008·3)
1 312 102·0 
(1 163 063·8 
to 
1 472 494·4)
1 468 000·0 









(22 961·5 to 
28 096·0)
22 707·2 
(20 288·0 to 
25 308·0)
20 786·9 








Neoplasms 151 550·6 
(148 429·7 to 
155 144·0)
189 094·4 
(185 939·0 to 
192 035·5)
213 221·0 





















































































































































(18 712·9 to 
19 405·6)
18 345·5 























Colon and rectum 
cancer
11 021·7 
(10 741·7 to 
11 482·7)
14 637·5 
(14 356·4 to 
14 918·1)
17 197·2 























Liver cancer 13 311·9 
(12 450·1 to 
14 010·2)
18 332·3 
(17 719·9 to 
18 813·2)
21 143·8 















































































































 (–6·7 to 
7·2)





























































































































(23 862·3 to 
25 086·9)
32 059·3 
(31 518·1 to 
32 631·0)
36 441·0 
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(12 668·7 to 
13 875·4)
15 107·8 
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Cardiovascular diseases 266 709·6 
(258 611·1 to 
274 986·6)
321 851·2 
(312 966·3 to 
330 487·6)
353 120·9 























Rheumatic heart disease 13 277·2 
(11 854·4 to 
14 558·1)
11 235·5 


























Ischaemic heart disease 118 996·9 
(115 809·8 to 
122 723·6)
153 547·6 
(149 867·7 to 
156 971·0)
174 611·1 























Cerebrovascular disease 95 306·8 
(91 616·6 to 
100 606·2)
111 916·0 
(108 069·6 to 
115 501·2)
116 445·1 























Ischaemic stroke 37 687·2 
(35 505·5 to 
39 624·6)
46 909·9 
(44 168·6 to 
49 455·6)
51 897·4 























Haemorrhagic stroke 57 619·6 
(55 206·4 to 
61 574·1)
65 006·1 
(63 154·6 to 
66 941·1)
64 547·7 





























(11 603·8 to 
15 049·4)
16 335·1 
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Other cardiovascular and 
circulatory diseases
13 076·2 
(10 976·0 to 
14 815·8)
13 063·8 
(11 561·4 to 
15 422·4)
14 771·4 


























(79 815·5 to 
92 631·5)
86 665·1 
(81 193·2 to 
92 630·9)
92 528·7 


























(53 271·2 to 
64 128·3)
59 572·5 
(56 816·4 to 
62 571·2)
63 434·3 















































































































































































Asthma 23 840·9 
(19 339·2 to 
28 695·4)
22 827·4 
(18 531·6 to 
27 887·8)
23 720·5 
























































































Cirrhosis and other 
chronic liver diseases
28 184·1 
(26 769·7 to 
29 706·9)
36 122·1 
(34 848·4 to 
39 549·1)
38 856·7 















































































































































Digestive diseases 32 345·7 
(28 585·3 to 
34 769·7)
33 020·0 
(30 716·0 to 
35 440·1)
34 368·9 
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Neurological disorders 64 973·1 
(50 343·0 to 
80 732·5)
87 251·9 
(67 830·9 to 
107 955·1)
103 580·0 























Alzheimer’s disease and 
other dementias
13 024·5 
(11 052·7 to 
15 479·9)
20 912·2 
(17 919·7 to 
24 689·5)
28 764·1 





















































Epilepsy 12 420·8 
(10 285·4 to 
14 852·0)
13 435·2 
(11 142·0 to 
16 031·4)
13 492·2 



















































































Migraine 29 843·4 
(19 092·9 to 
41 793·9)
39 485·3 
(25 341·5 to 
55 187·3)
45 121·9 





















































































Mental and substance use 
disorders
110 918·3 
(83 056·1 to 
141 228·0)
145 067·1 
(108 650·3 to 
183 887·6)
162 509·3 
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(12 607·6 to 
19 100·6)
16 244·7 























Drug use disorders 14 247·5 
(11 250·4 to 
17 370·8)
18 009·0 
(14 444·2 to 
21 739·6)
20 394·2 



























(10 018·1 to 
15 694·7)
14 788·8 



















































































































































Depressive disorders 29 503·5 
(20 318·2 to 
40 109·0)
39 052·4 
(26 930·5 to 
52 535·2)
44 208·4 


























(16 150·4 to 
31 868·1)
30 670·3 
(21 102·1 to 
41 462·3)
34 104·6 



















































































Anxiety disorders 17 893·2 
(12 472·9 to 
24 294·6)
23 364·5 
(16 285·6 to 
31 632·0)
26 417·4 
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blood, and endocrine 
diseases
81 744·6 
(71 204·2 to 
94 535·9)
112 751·7 
(98 101·9 to 
131 367·5)
133 747·8 























Diabetes mellitus 27 475·9 
(23 282·7 to 
32 608·1)
45 989·7 
(38 695·1 to 
54 713·4)
57 233·7 























































Chronic kidney disease 21 597·2 
(20 094·0 to 
23 354·9)
29 187·2 
(27 250·7 to 
31 463·0)
35 032·4 





























(10 615·3 to 
12 891·9)
14 660·6 
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Musculoskeletal disorders 86 655·4 
(63 137·9 to 
112 703·8)
117 031·2 
(85 442·0 to 
152 359·0)
140 030·6 
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Low back and neck pain 55 941·4 
(39 562·5 to 
73 187·3)
72 599·3 
(51 532·0 to 
94 807·4)
86 584·5 























Low back pain 39 129·9 
(27 512·7 to 
51 797·6)
48 853·4 
(34 564·0 to 
64 073·6)
57 648·2 























Neck pain 16 811·5 
(11 404·8 to 
23 792·2)
23 745·9 
(16 214·4 to 
33 438·2)
28 936·3 
























































(13 162·2 to 
26 102·7)
26 754·8 
(18 664·4 to 
36 839·1)
30 528·6 


























(127 834·6 to 
209 136·6)
183 247·3 
(141 607·2 to 
236 700·6)
196 036·1 























Congenital birth defects 68 393·0 
(53 592·7 to 
84 283·8)
58 286·5 
(48 759·3 to 
66 905·7)
50 429·8 
























































(21 339·9 to 
34 673·0)
22 936·6 
(19 833·8 to 
26 150·9)
18 563·8 
















































































































































































































































































Other congenital birth 
defects
18 906·7 
(10 942·1 to 
30 995·8)
18 317·5 
(12 204·8 to 
26 209·6)
16 626·6 























Skin and subcutaneous 
diseases
41 366·2 
(28 152·7 to 
59 346·6)
51 550·5 
(35 306·4 to 
73 530·7)
57 394·0 
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(10 169·9 to 
21 752·0)
15 836·0 















































































































































































Sense organ diseases 39 443·2 
(27 342·1 to 
54 552·7)
54 826·6 
(38 158·5 to 
76 040·8)
66 701·9 


















































































































































Age-related and other 
hearing loss
21 193·7 
(14 943·8 to 
29 581·7)
29 673·0 
(20  837·2 to 
41 494·7)
36 287·5 
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Injuries 259 714·5 
(242 647·1 to 
276 817·9)
259 792·1 
(242 234·6 to 
280 976·8)
255 434·3 























Transport injuries 70 430·3 
(67 012·4 to 
74 545·4)
80 802·1 
(76 835·3 to 
85 315·6)
78 051·8 























Road injuries 64 788·4 
(61 744·3 to 
68 397·9)
74 299·1 
(71 021·9 to 
78 088·0)
71 395·0 


























(22 795·5 to 
28 090·8)
26 131·7 
(24 588·0 to 
28 158·5)
24 001·5 
























































(10 510·3 to 
12 944·1)
15 105·0 
(13 758·6 to 
16 396·3)
14 937·5 























Motor vehicle road 
injuries
24 319·9 
(20 644·9 to 
27 442·2)
27 217·7 
(24 983·6 to 
30 653·8)
26 211·8 



















































































Unintentional injuries 121 695·5 
(109 006·9 to 
134 119·5)
111 226·3 
(98 814·1 to 
125 226·5)
107 423·5 
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Falls 26 607·6 
(22 592·9 to 
31 276·8)
31 258·7 
(26 220·2 to 
37 276·0)
35 773·8 























Drowning 34 779·0 
(29 934·2 to 
37 903·4)
22 886·7 
(20 014·2 to 
24 143·1)
16 809·0 





















































































Exposure to mechanical 
forces
12 931·3 
(11 440·5 to 
14 960·9)
12 360·8 
























































































































































































































































































































































































































































(52 622·2 to 
60 351·8)
61 630·8 
(56 736·9 to 
64 509·4)
58 717·9 
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[26·1–35·4]) from 2006 to 2016. Age­standardised DALY 
rates from self­harm (decreased by 17·7% [12·9–21·2]) and 
interpersonal violence (12·0% [7·0–16·1]) have both 
decreased by more than 10% since 2006. Age­standardised 
DALY rates resulting from conflict and terrorism increased 
by 97·4% (25·7–240·9) from 2006 to 2016; this rise was 
primarily driven by ongoing conflicts in north Africa, the 
Middle East, and sub­Saharan Africa. This result represents 
an increase in all­age DALYs of 114·0% (36·2–271·3) from 
2006 to 2016.
Global DALY counts in 2016 for causes that were 
estimated separately for the first time are as follows: 
alcoholic cardiomyopathy 2·59 million (95% UI 
2·06 million to 3·24 million), urogenital congenital 
anomalies 1·09 million (0·86 million to 1·31 million), 
congenital musculoskeletal and limb anomalies 
2·26 million (1·66 million to 2·99 million), digestive 
congenital anomalies 3·34 million (2·67 million to 
4·96 million), Zika virus disease 5100 (3400–8000), Guinea 
worm disease 0·87 (0·5–1·35), self­harm by firearm 
2·85 million (2·39 million to 3·59 million), sexual 
violence 1·37 million (0·92 million to 1·95 million), 
myocarditis 1·37 million (1·12 million to 1·51 million), 
drug­susceptible tuberculosis 39·9 million (38·1 million 
to 41·9 million), multidrug­resistant tuberculosis without 
extensive drug resistance 3·32 million (2·79 million to 
All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
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Self-harm 36 069·6 
(33 180·8 to 
38 321·5)
37 517·7 
(34 901·0 to 
39 462·7)
35 149·6 





















































Self-harm by other 
specified means
33 118·1 
(30 211·8 to 
35 109·1)
34 642·5 
(32 074·6 to 
36 526·4)
32 296·4 























Interpersonal violence 20 942·3 
(17 360·5 to 
23 608·2)
24 113·2 
(19 792·0 to 
26 579·9)
23 568·3 
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Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. ··=not defined (used for asymptomatic causes, epidemics, and outbreaks). 
DALYs=disability-adjusted life-years. G6PD=glucose-6-phosphate dehydrogenase. *Percentage changes that are statistically significant.
Table 1: Global all-age DALYs and age-standardised DALY rates in 1990, 2006, and 2016 with mean percentage changes between 1990 and 2016, 2006 and 2016, and 1990 and 2016 for 
all causes  
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3·91 million), extensively drug­resistant tuberculosis 
369 000 (301 000–445 000), drug­susceptible HIV/AIDS­
tuberculosis 11·7 million (8·15 million to 15·5 million), 
multidrug­resistant HIV/AIDS­tuberculosis without ex­
tensive drug resistance 0·98 million (0·60 million to 
1·48 million), and extensively drug­resistant HIV/AIDS­
tuberculosis 57 300 (34 500–89 400; table 1).
Changes in leading causes of disease burden over time 
and SDI quintiles
The leading Level 3 causes of global DALYs in 1990 were 
lower respiratory infections, diarrhoeal diseases, and 
ischaemic heart disease (figure 2A). By 2016, lower 
respiratory infections had decreased in relative rank to 
the third­leading cause, whereas diarrhoeal diseases were 
fifth and ischaemic heart disease rose to first. The leading 
30 causes of DALYs by SDI quintile varied considerably 
(figure 2B–F). CMNN causes were dominant in the low­
SDI quintile, occupying 11 of the top 15 causes in 2016. 
NCDs were more commonly among the leading causes of 
DALYs with successively higher levels of SDI, occupying 
12 of the top 15 causes in the high­SDI quintile in 2016.
For low SDI, only two NCD causes (congenital birth 
defects and ischaemic heart disease) ranked in the top 
ten in 2016, compared with all of the top ten for high 
SDI. Of the leading 30 causes from 2006 to 2016, 
HIV/AIDS had the largest decrease in age­standardised 
DALY rates for low, low­middle, and middle SDI. For 
high­middle SDI, the largest decrease was for lower 
respiratory infection, and for high SDI, the largest 
decrease was for road injuries. At low­middle SDI, 14 of 
the leading 30 causes in 2016 were NCDs, whereas 
13 were CMNN causes and three were injuries, compared 
with middle SDI, where seven were CMNN causes, 19 
were NCDs, and four were injuries. The leading 
seven causes for low, low­middle, and middle SDI 
quintiles all decreased in age­standardised DALY rates 
from 2006 to 2016.
At high­middle and high SDI, the leading three causes 
of DALYs remained the same from 2006 to 2016 
(ischaemic heart disease, low back and neck pain, and 
cerebrovascular disease). Two of the leading 30 causes 
for high­middle SDI were CMNN causes in 2016, 
whereas 24 were NCDs and four were injuries, compared 
with high SDI, where one was a CMNN cause, 26 were 
NCDs, and three were injuries. The leading five causes 
for high­middle SDI decreased in age­standardised DALY 
rates from both 1990 to 2006 and 2006 to 2016, although 
this pattern did not hold for high SDI, where just the 
leading cause decreased over both intervals. Road 
injuries and falls are the only injuries that appear across 
all five SDI quintiles; self­harm appears in all quintiles 
except for low SDI. Ischaemic heart disease and 
cerebrovascular disease appear in the leading 13 causes 
across all SDI quintiles. HIV/AIDS appears in the leading 
ten causes for all quintiles except for high and high­
middle SDI, where it did not appear in the leading 30.
Regional and country-specific HALE and DALYs in 2016
In 2016, HALE at birth was highest in Singapore for both 
females (75·2 years [95% UI 71·9–78·6]) and males 
(72·0 years [68·8–75·1]) and lowest for females in the 
Central African Republic (45·6 years [42·0–49·5]) and for 
males in Lesotho (41·5 [39·0–44·0]; table 2 and 3). In 2016, 
HALE at birth was greater than 70 years in only 12 locations 
for males and was greater than this threshold in 49 locations 
for females. HALE at birth was less than 50 years for both 
sexes in three locations: the Central African Republic, 
Lesotho, and Afghanistan. Between 1990 and 2016, HALE 
at birth increased for males in 160 locations and for females 
in 167 locations. For males, the largest increase occurred in 
Ethiopia, rising from 39·3 years (37·5–41·0) in 1990 to 
57·2 years (54·1–60·45) in 2016. For females, the largest 
increase occurred in the Maldives, rising from 53·6 
(51·1–56·1) in 1990 to 70·3 (66·3–73·7) in 2016. Over the 
same time period, HALE at birth decreased in just 
1990, at birth 2006, at birth 2016, at birth
































































































































Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. GBD=Global Burden of Disease. HALE=healthy life expectancy. 
SDI=Socio-demographic index.
Table 2: Global, regional, and GBD location-specific life expectancy and HALE at birth, by sex, in 1990, 2006, and 2016
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two countries for females (Lesotho and South Africa) and 
three for males (Lesotho, South Africa, and Swaziland). In 
2016, HALE at age 65 years was highest in Singapore for 
males (15·1 years [13·4–16·8]) and Japan for females 
(18·7 years [17·1–20·0]), whereas it was lowest for males in 
Lesotho (6·9 years [6·0–7·8]) and females in Afghanistan 
(7·4 years [6·5–8·3]).
The leading Level 3 causes of DALYs in 2016 varied by 
country, but with regional commonalities, described on 
the basis of GBD regions12 in figure 3. Across the 
46 countries within sub­Saharan Africa, the leading Level 3 
cause of DALYs for females was either HIV/AIDS 
(17 countries), malaria (13 countries), or diarrhoeal diseases 
(nine countries). Cerebrovascular disease, ischaemic heart 
disease, and low back and neck pain were the most 
common leading Level 3 causes of all­age DALYs for 
females in all GBD regions except for Oceania, Andean 
Latin America and central Latin America, and all regions 
of sub­Saharan Africa. Among the 34 countries in the 
high­income super­region, low back and neck pain was the 
leading cause of DALYs for females in all but three 
countries. Exceptions within the region were Greece and 
the USA, for which ischaemic heart disease was the 
leading cause of DALYs, and Greenland, where self­harm 
was the highest cause of DALYs for females (and for 
males). For males, these regional commonalities also 
occurred, but with some notable differences in the leading 
causes by location compared with females. Leading causes 
of DALYs for males in sub­Saharan Africa were broadly 
similar to those for females: HIV/AIDS (16 countries), 
malaria (11 countries), or lower respiratory infections 
(nine countries). Cerebrovascular disease or ischaemic 
heart disease was the leading cause of all­age DALYs for 
males in almost all GBD regions except for Andean Latin 
America, central Latin America, tropical Latin America, 
high­income Asia Pacific, and all regions of sub­Saharan 
Africa. Exceptions within the regions included Greenland, 
where self­harm was the leading cause of DALYs for males 
in 2016, Peru, where lower respiratory infection was the 
leading cause, and Nicaragua, where chronic kidney 
disease was the leading cause. The leading cause of DALYs 
for both males and females in Syria and Iraq was conflict 
and terrorism, reflecting the ongoing conflict.
Epidemiological transition
The shift in the global burden of DALYs from CMNN to 
NCDs is a clear indicator of the epidemiological 
transition.21 The ratios of DALYs from NCDs to those from 
CMNN diseases in 1990, 1995, 2000, 2006, 2010, and 2016 
are shown by SDI and at the global, GBD regional, and 
GBD super­regional scales for both males and females in 
figure 4. In 2016, 17 (of 21) GBD regions and six (of seven) 
GBD super­regions had a ratio of more than 1 for either 
men or women, representing the shift to more DALYs 
from NCDs than from CMNN diseases, compared with 
13 regions and five super­regions in 1990. In 2016, females 
had more DALYs due to NCDs relative to CMNN causes 
than did males, with higher ratios in 14 regions. This 
figure also shows how these ratios shift with increasing 
SDI, with 18·5 as the 2016 ratio for high SDI for men and 
20·5 for women and 0·52 for men in low SDI and 0·57 
for women. Several regions showed large shifts toward 
more NCD DALYs than CMNN DALYs, with 12 regions 
doubling in ratio from 1990 to 2016 for females and 
11 regions doubling for males over the same time period.
Expected age­standardised YLL rates decreased sub­
stantially with increasing SDI, most notably because of 
decreases in CMNN causes, such as diarrhoea, lower 
respiratory infections, and other common infectious 
diseases; NTDs and malaria; neonatal disorders; nu­
tritional deficiencies; and HIV/AIDS and tuberculosis 
(figure 5A). Several causes had their largest expected age­
standardised rates at intermediate levels of SDI, such as 
diabetes, urogenital, blood, and endocrine diseases; 
cardio vascular diseases; and chronic respiratory diseases. 
Causes that increased in expected age­standardised YLL 
rates with increasing SDI included neoplasms and 
neurological disorders. Much less variation was estimated 
1990, at age 65 years 2006, at age 65 years 2016, at age 65 years
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Data in parentheses are 95% uncertainty intervals. To download the data in this table, please visit the Global Health Data Exchange. GBD=Global Burden of Disease. HALE=healthy life expectancy. 
SDI=Socio-demographic index.
Table 3: Global, regional, and GBD location-specific life expectancy and HALE at age 65 years, by sex, in 1990, 2006, and 2016
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for expected age­standardised YLD rates with SDI than 
for YLL rates. Although the relationship between 
disability and SDI was generally constant for most Level 2 
causes, nutritional deficiencies, NTDs, and malaria 
resulted in greater than expected levels of disability at 
lower SDI.
Compared with YLLs and YLDs expressed as all­age 
rates, the consequences of differences in population age 
structure become apparent for a number of causes 
(figure 5B). Cardiovascular diseases, in particular, result 
in greater YLLs at higher SDI in terms of all­age rates, 
reflecting the older age of populations at higher levels 
of SDI. By contrast, the pattern observed when 
standardising for age structure—YLLs accruing at 
intermediate SDI—highlights health loss from diseases 
that typically manifest at older ages undistorted by the 
lower overall age structure of the populations. The 
expected all­age YLD rates generally increased with 
rising SDI, particularly for mental and substance use 
disorders and musculoskeletal disorders, although 
variation with SDI remained substantially lower than 
for YLLs.
Figure 1: Trends of total DALYs (A) and age-standardised DALY rates (B) from 1990 to 2016 for GBD Level 1 cause groups by SDI quintile
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1 Lower respiratory infection 1 Ischaemic heart disease 1 Ischaemic heart disease
2 Diarrhoeal diseases 2 Lower respiratory infection 2 Cerebrovascular disease
3 Ischaemic heart disease 3 Diarrhoeal diseases 3 Lower respiratory infection
4 Neonatal preterm birth 4 Cerebrovascular disease 4 Low back and neck pain
5 Cerebrovascular disease 5 HIV/AIDS 5 Diarrhoeal diseases
6 Measles 6 Neonatal preterm birth 6 Road injuries
7 Congenital defects 7 Malaria 7 Sense organ diseases
8 Neonatal encephalopathy 8 Road injuries 8 COPD
9 Tuberculosis 9 Low back and neck pain 9 Neonatal preterm birth
10 Road injuries 10 Neonatal encephalopathy 10 HIV/AIDS
11 Malaria 11 COPD 11 Skin diseases
12 COPD 12 Congenital defects 12 Diabetes
13 Low back and neck pain 13 Tuberculosis 13 Malaria
14 Other neonatal 14 Sense organ diseases 14 Congenital defects
15 Skin diseases 15 Skin diseases 15 Neonatal encephalopathy
16 Sense organ diseases 16 Diabetes 16 Migraine
17 Self-harm 17 Migraine 17 Depressive disorders
18 Protein-energy malnutrition 18 Depressive disorders 18 Tuberculosis
19 Drowning 19 Self-harm 19 Lung cancer
20 Meningitis 20 Other neonatal 20 Falls
21 Migraine 21 Iron-deficiency anaemia 21 Self-harm
22 Depressive disorders 22 Lung cancer 22 Chronic kidney disease
23 Diabetes 23 Falls 23 Iron-deficiency anaemia
24 Iron-deficiency anaemia 24 Chronic kidney disease 24 Other musculoskeletal
25 Falls 25 Other musculoskeletal 25 Alzheimer's disease
26 Tetanus 26 Protein-energy malnutrition 26 Anxiety disorders
27 Neonatal sepsis 27 Neonatal sepsis 27 Other neonatal
28 Lung cancer 28 Meningitis 28 Asthma
29 Asthma 29 Interpersonal violence 29 Neonatal sepsis
30 Chronic kidney disease 30 Anxiety disorders 30 Interpersonal violence
31 Drowning31 Interpersonal violence 31 Meningitis
32 Asthma33 Other musculoskeletal 33 Protein-energy malnutrition
33 Alzheimer's disease34 Anxiety disorders 38 Drowning
34 Measles36 HIV/AIDS 85 Measles
79 Tetanus43 Alzheimer's disease 116 Tetanus
1 Lower respiratory infection 1 Malaria 1 Lower respiratory infection
2 Diarrhoeal diseases 2 Diarrhoeal diseases 2 Malaria
3 Malaria 3 Lower respiratory infection 3 Diarrhoeal diseases
4 Measles 4 HIV/AIDS 4 HIV/AIDS
5 Protein-energy malnutrition 5 Neonatal preterm birth 5 Neonatal preterm birth
6 Neonatal preterm birth 6 Neonatal encephalopathy 6 Neonatal encephalopathy
7 Tuberculosis 7 Tuberculosis 7 Tuberculosis
8 Neonatal encephalopathy 8 Protein-energy malnutrition 8 Ischaemic heart disease
9 Meningitis 9 Congenital defects 9 Congenital defects
10 Congenital defects 10 Meningitis 10 Protein-energy malnutrition
11 HIV/AIDS 11 Neonatal sepsis 11 Meningitis
12 Neonatal sepsis 12 Ischaemic heart disease 12 Neonatal sepsis
13 Other neonatal 13 Other neonatal 13 Cerebrovascular disease
14 STDs 14 Cerebrovascular disease 14 Road injuries
15 Ischaemic heart disease 15 STDs 15 Other neonatal
16 Tetanus 16 Road injuries 16 Iron-deficiency anaemia
17 Cerebrovascular disease 17 Iron-deficiency anaemia 17 STDs
18 Conflict and terror 18 Measles 18 Skin diseases
19 Road injuries 19 Skin diseases 19 Low back and neck pain
20 Whooping cough 20 Whooping cough 20 Sense organ diseases
21 Iron-deficiency anaemia 21 Sense organ diseases 21 Diabetes
22 Skin diseases 22 Low back and neck pain 22 Depressive disorders
23 Low back and neck pain 23 COPD 23 Conflict and terror
24 Sense organ diseases 24 Diabetes 24 COPD
25 Drowning 25 Drowning 25 Migraine
26 COPD 26 Depressive disorders 26 Whooping cough
27 Hemoglobinopathies 27 Asthma 27 Asthma
28 Asthma 28 Haemoglobinopathies 28 Falls
29 Falls 29 Falls 29 Haemoglobinopathies
30 Depressive disorders 30 Migraine 30 Drowning
33 Tetanus32 Diabetes 34 Measles
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1 Diarrhoeal diseases 1 Ischaemic heart disease
2 Lower respiratory infection 2 Diarrhoeal diseases
3 Neonatal preterm birth 3 Lower respiratory infection
4 HIV/AIDS 4 Neonatal preterm birth
5 Ischaemic heart disease 5 Cerebrovascular disease
6 Malaria 6 Malaria
7 Malaria 7 Neonatal encephalopathy 7 COPD
8 Other neonatal 8 Tuberculosis 8 Neonatal encephalopathy
9 Ischaemic heart disease 9 Cerebrovascular disease 9 HIV/AIDS
10 Congenital defects 10 Other neonatal 10 Road injuries
11 COPD 11 Congenital defects 11 Tuberculosis
12 Cerebrovascular disease 12 COPD 12 Iron-deficiency anaemia
13 Tetanus 13 Road injuries 13 Sense organ diseases
14 Protein-energy malnutrition 14 Iron-deficiency anaemia 14 Low back and neck pain
15 Iron-deficiency anaemia 15 Sense organ diseases 15 Congenital defects
16 Road injuries 16 Low back and neck pain 16 Skin diseases
17 Meningitis 17 Measles 17 Diabetes
18 Drowning 18 Skin diseases 18 Migraine
19 Intestinal infectious 19 Self-harm 19 Other neonatal
20 Sense organ diseases 20 Migraine 20 Depressive disorders
21 Neonatal sepsis 21 Diabetes 21 Self-harm
22 Low back andneck pain 22 Meningitis 22 Chronic kidney disease
23 Skin diseases 23 Neonatal sepsis 23 Falls
24 Self-harm 24 Protein-energy malnutrition 24 Neonatal sepsis
25 Asthma 25 Depressive disorders 25 Other musculoskeletal
26 Neonatal haemolytic 26 Intestinal infectious 26 Meningitis
27 Migraine 27 Falls 27 Asthma
28 Falls 28 Drowning 28 Protein-energy malnutrition
29 STDs 29 Chronic kidney disease 29 Intestinal infectious
30 Depressive disorders 30 Asthma 30 Anxiety disorders
31 Other musculoskeletal32 Chronic kidney disease 31 Drowning
32 STDs33 Diabetes 45 STDs
33 Anxiety disorders34 Other musculoskeletal 58 Measles
37 Neonatal haemolytic37 HIV/AIDS 59 Neonatal haemolytic
42 Tetanus42 Anxiety disorders 96 Tetanus
1 Lower respiratory infection 1 Ischaemic heart disease 1 Ischaemic heart disease
2 Cerebrovascular disease 2 Cerebrovascular disease 2 Cerebrovascular disease
3 Neonatal preterm birth 3 Road injuries 3 Road injuries
4 Diarrhoeal diseases 4 HIV/AIDS 4 Low back and neck pain
5 Ischaemic heart disease 5 Lower respiratory infectio 5 Sense organ diseases
6 Congenital defects 6 COPD 6 Diabetes
7 Road injuries 7 Low back and neck pain 7 COPD
8 COPD 8 Neonatal preterm birth 8 Skin diseases
9 Neonatal encephalopathy 9 Sense organ diseases 9 Lower respiratory infection
10 Tuberculosis 10 Congenital defects 10 HIV/AIDS
11 Low back and neck pain 11 Diabetes 11 Lung cancer
12 Drowning 12 Skin diseases 12 Chronic kidney disease
13 Self-harm 13 Tuberculosis 13 Congenital defects
14 Skin diseases 14 Lung cancer 14 Neonatal preterm birth
15 Sense organ diseases 15 Depressive disorders 15 Migraine
16 Diabetes 16 Migraine 16 Depressive disorders
17 Interpersonal violence 17 Diarrhoeal diseases 17 Liver cancer
18 Depressive disorders 18 Self-harm 18 Other musculoskeletal
19 Migraine 19 Chronic kidney disease 19 Self-harm
20 Other neonatal 20 Neonatal encephalopathy 20 Interpersonal violence
21 Chronic kidney disease 21 Liver cancer 21 Falls
22 Stomach cancer 22 Interpersonal violence 22 Alzheimer's disease
23 Measles 23 Other musculoskeletal 23 Tuberculosis
24 Liver cancer 24 Stomach cancer 24 Stomach cancer
25 Lung cancer 25 Falls 25 Anxiety disorders
26 Falls 26 Drowning 26 Diarrhoeal diseases
27 Asthma 27 Anxiety disorders 27 Iron-deficiency anaemia
28 Other musculoskeletal 28 Asthma 28 Hypertensive heart disease
29 Anxiety disorders 29 Iron-deficiency anaemia 29 Asthma
30 Iron-deficiency anaemia 30 Alzheimer's disease 30 Neonatal encephalopathy
31 Other neonatal32 Hypertensive heart disease 33 Drowning
32 Hypertensive heart disease42 Alzheimer's disease 46 Other neonatal
82 Measles98 HIV/AIDS 121 Measles
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1 Ischaemic heart disease 1 Ischaemic heart disease 1 Ischaemic heart disease
2 Cerebrovascular disease 2 Cerebrovascular disease 2 Cerebrovascular disease
3 Lower respiratory infection 3 Low back and neck pain 3 Low back and neck pain
4 Road injuries 4 Road injuries 4 Sense organ diseases
5 Low back and neck pain 5 Sense organ diseases 5 Road injuries
6 Neonatal preterm birth 6 Skin diseases 6 Skin diseases
7 Congenital defects 7 Depressive disorders 7 Diabetes
8 COPD 8 COPD 8 Depressive disorders
9 Sense organ diseases 9 Migraine 9 Migraine
10 Skin diseases 10 Lung cancer 10 Lung cancer
11 Lung cancer 11 Lower respiratory infection 11 Falls
12 Falls 12 Congenital defects 12 COPD
13 Self-harm 13 Diabetes 13 Alzheimer's disease
14 Migraine 14 Self-harm 14 Lower respiratory infection
15 Depressive disorders 15 Falls 15 Self-harm
16 Diabetes 16 Neonatal preterm birth 16 Congenital defects
17 Diarrhoeal diseases 17 Alcohol use disorders 17 Anxiety disorders
18 Stomach cancer 18 Interpersonal violence 18 Chronic kidney disease
19 Drowning 19 Drug use disorders 19 Alcohol use disorders
20 Interpersonal violence 20 Alzheimer's disease 20 Other musculoskeletal
21 Neonatal encephalopathy 21 Stomach cancer 21 Drug use disorders
22 Alcohol use disorders 22 Anxiety disorders 22 Neonatal preterm birth
23 Drug use disorders 23 Chronic kidney disease 23 Colorectal cancer
24 Anxiety disorders 24 Cardiomyopathy 24 Stomach cancer
25 Chronic kidney disease 25 Other musculoskeletal 25 Interpersonal violence
26 Tuberculosis 26 Colorectal cancer 26 Oral disorders
27 Alzheimer's disease 27 Liver cancer 27 Liver cancer
28 Asthma 28 Oral disorders 28 Cardiomyopathy
29 Other neonatal 29 Drowning 29 Osteoarthritis
30 Nature disaster 30 Tuberculosis 30 Breast cancer
31 Osteoarthritis31 Other musculoskeletal 33 Asthma
32 Breast cancer32 Liver cancer 40 Drowning
33 Asthma33 Colorectal cancer 45 Tuberculosis
36 Neonatal encephalopathy34 Cardiomyopathy 47 Neonatal encephalopathy
46 Other neonatal35 Oral disorders 59 Diarrhoeal diseases
50 Diarrhoeal diseases40 Breast cancer 62 Other neonatal
129 Nature disaster42 Osteoarthritis 145 Nature disaster
1 Ischaemic heart disease 1 Ischaemic heart disease 1 Ischaemic heart disease
2 Low back and neck pain 2 Low back and neck pain 2 Low back and neck pain
3 Cerebrovascular disease 3 Cerebrovascular disease 3 Cerebrovascular disease
4 Road injuries 4 Lung cancer 4 Lung cancer
5 Lung cancer 5 Skin diseases 5 Alzheimer's disease
6 Skin diseases 6 Sense organ diseases 6 Sense organ diseases
7 Sense organ diseases 7 Diabetes 7 Skin diseases
8 Migraine 8 Alzheimer's disease 8 Diabetes
9 Depressive disorders 9 Depressive disorders 9 COPD
10 Diabetes 10 Migraine 10 Depressive disorders
11 Self-harm 11 Road injuries 11 Migraine
12 COPD 12 COPD 12 Falls
13 Falls 13 Self-harm 13 Self-harm
14 Alzheimer's disease 14 Falls 14 Road injuries
15 Colorectal cancer 15 Drug use disorders 15 Drug use disorders
16 Congenital defects 16 Colorectal cancer 16 Colorectal cancer
17 Anxiety disorders 17 Other musculoskeletal 17 Other musculoskeletal
18 Other musculoskeletal 18 Anxiety disorders 18 Anxiety disorders
19 Lower respiratory infection 19 Lower respiratory infection 19 Chronic kidney disease
20 Drug use disorders 20 Chronic kidney disease 20 Lower respiratory infection
21 Stomach cancer 21 Breast cancer 21 Oral disorders
22 Breast cancer 22 Oral disorders 22 Other cardiovascular
23 Other cardiovascular 23 Other cardiovascular 23 Breast cancer
24 Neonatal preterm birth 24 Congenital defects 24 Osteoarthritis
25 Oral disorders 25 Stomach cancer 25 Pancreatic cancer
26 Asthma 26 Asthma 26 Congenital defects
27 Chronic kidney disease 27 Alcohol use disorders 27 Stomach cancer
28 Alcohol use disorders 28 Pancreatic cancer 28 Alcohol use disorders
29 Interpersonal violence 29 Osteoarthritis 29 Asthma
30 HIV/AIDS 30 Liver cancer 30 Liver cancer
31 Neonatal preterm birth32 Pancreatic cancer 37 Neonatal preterm birth
33 Interpersonal violence34 Osteoarthritis 42 Interpersonal violence
60 HIV/AIDS36 Liver cancer 71 HIV/AIDS












































































































































































































































































































































































































Figure 2: Leading 30 Level 3 causes of total DALYs for 1990, 2006, and 2016, with percentage change in number of DALYs and all-age and age-standardised DALY rates, overall and by SDI quintile
Overall (A). Low SDI (B). Low-middle SDI (C). Middle SDI (D). High-middle SDI (E). High SDI (F). Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. 
For the time period of 1990–2006 and 2006–16, three measures of change are shown: percentage change in the number of DALYs, percentage change in the all-age DALY rate, and percentage change in 
the age-standardised DALY rate. Statistically significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. DALYs=disability-adjusted life-years. STDs=sexually transmitted diseases.
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The proportion of DALYs due to YLDs versus YLLs has 
shifted distinctly since 1990, and these changes are 
shown in figure 6. More all­age DALYs as a result of YLDs 
rather than YLLs indicates a reduction in premature 
death, with individuals living longer with disability than 
previously. Globally, 95·9% of countries increased in the 
proportion of all­age DALYs due to YLDs from 
1990 to 2016. In 2016, Kuwait (0·64), Qatar (0·63), and 
Bahrain (0·60) had the highest ratios of DALYs due to 
YLDs, whereas Chad (0·14), Niger (0·14), and the Central 
African Republic (0·13) had the lowest. This finding is a 
change from 1990, when the highest three proportions 
were for Andorra (0·49), Kuwait (0·48), and 
Iceland (0·47), and the lowest three were for 
Burundi (0·08), Malawi (0·08), and Niger (0·06).
Observed versus expected total and cause-specific burden
As shown in figure 7, 83 countries had greater than 
expected age­standardised DALY rates on the basis of SDI 
in 2016 (a ratio of observed to expected age­standardised 
DALY rate of greater than 1), generally within central 
Europe, eastern Europe, and central Asia (20 of 
29 countries) or in the super­region of sub­Saharan Africa 
(24 of 46 countries). Among the 34 locations in the five 
regions within the high­income GBD super­region, three 
had greater than expected DALYs relative to their SDI. The 
five locations with the lowest level of age­standardised 
DALYs relative to the level expected on the basis of SDI 
were Nicaragua, Costa Rica, the Maldives, Peru, and 
Israel. Countries within western Europe (eg, France, 
Norway, and Iceland), western sub­Saharan Africa (eg, 
The Gambia, Senegal, and Liberia), eastern sub­Saharan 
Africa (eg, Ethiopia, Rwanda, and Burundi), east Asia (eg, 
China), and a subset of countries in south and southeast 
Asia (eg, Bhutan and Bangladesh) all had ratios of 
observed to expected DALY rates of less than 1 in 2016. 
The five locations with the highest age­standardised DALY 
rates relative to the rates expected on the basis of SDI were 
Lesotho, Swaziland, South Africa, Fiji, and Botswana, with 
Lesotho’s ratio of observed to expected measured at 2·43 
in 2016.
Worldwide, ischaemic heart disease and stroke 
remained the two leading causes of DALYs, and 
expected levels were close to those observed at a global 
scale, with ratios of 0·84 for ischaemic heart disease 
and 1·0 for stroke (figure 8). The ratio of observed to 
expected DALYs ranged from 0·24 in Qatar to 3·33 in 
Ukraine for ischaemic heart disease and from 0·32 in 
Oman to 2·98 in Bulgaria for stroke. This ratio was 
less than 1 for 114 of 167 global locations for ischaemic 
heart disease and 91 of 145 for stroke. Low back and 
neck pain resulted in fewer than expected DALYs 
globally, with a ratio of 0·95 globally and 74 locations 
showing a ratio of less than 1. Of the ten leading causes 
for each location, observed levels of DALYs were 
frequently greater than expected on the basis of SDI 
for causes such as diabetes mellitus (ratio of observed 
to expected DALYs of greater than 1 in 95 global 
locations), sense organ diseases (79 locations), and 
skin and subcutaneous diseases (72 locations).
Causes that resulted in greater than expected DALYs for 
both sexes combined showed strong regional patterns. In 
the GBD high­income super­region, of the leading ten 
causes of DALYs, COPD had greater than expected DALYs 
in 14 of 34 locations and less than expected in none. 
Observed DALYs were frequently greater than expected 
for low back and neck pain (27 locations), although the 
ratio did not exceed 1·66 for any single location. Although 
drug use disorders were only within the leading ten 
causes for one location in the high­income super­region, 
the ratio of observed to expected DALYs in the USA was 
4·37. In addition to being the most common leading 
causes of DALYs, ischaemic heart disease and stroke 
were sources of more DALYs than expected for most 
locations in the central Europe, eastern Europe, and 
central Asia super­region. Here, the highest ratio of 
observed to expected DALYs was 3·33 for ischaemic heart 
disease and 2·98 for stroke. Mental and substance use 
disorders were also notable in the region for the high 
levels of observed DALYs relative to those expected, 
particularly in eastern Europe, where the ratio for the 
Level 4 cause of alcohol use disorders was 5·38 and 
ranged from 3·33 in Moldova to 5·7 in Russia. For 
locations in the super­region of Latin America and 
Caribbean, the burden from interpersonal violence was 
greater than expected, with a ratio of 3·37 for the super­
region and ranging from 1·68 in Ecuador to 7·22 in 
Venezuela. Diabetes was also a source of greater than 
expected burden in this super­region, with DALYs 
exceeding expected levels in 19 of 37 locations. 
Additionally, diabetes contributed to a higher burden of 
DALYs in many locations in the super­region of southeast 
Asia, east Asia, and Oceania, with ratios of observed to 
expected levels ranging from 0·68 in the Maldives to 
10·48 in Fiji.
In south Asia, neonatal encephalopathy due to birth 
asphyxia and trauma caused greater than expected DALYs 
for two countries, with ratios of 1·01 in Nepal and 2·72 in 
Pakistan. Ongoing conflicts in north Africa and the 
Middle East were reflected in higher than expected 
DALYs in seven of the 21 locations in the region. Patterns 
of observed DALYs compared with those expected in sub­
Saharan Africa were dominated by the ongoing effect of 
HIV/AIDS, particularly in southern sub­Saharan Africa. 
Observed levels of DALYs exceeded those expected in 
37 of 46 locations, ranging from a ratio of 8·10 in Burundi 
to 316·34 in Lesotho.
The five locations with the largest magnitude of 
improvement—a decrease in the difference between 
observed and expected all­cause age­standardised DALY 
rates from 1990 to 2016—included Greenland, the 
Maldives, Bermuda, Ethiopia, and Liberia. The 
five locations that showed the smallest decrease in the 
difference between observed and expected DALY rates 
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Figure 3: Leading Level 3 causes of all-age DALY rates by location for females (A) and males (B) in 2016
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over the period 1990–2016 were Lesotho, Swaziland, 
Syria, South Africa, and Botswana.
Discussion
General findings
Although the world has become healthier since 1990, 
this progress has been highly heterogeneous. From 1990 
to 2016, global HALE at birth increased. The total 
number of years of functional health lost (life expectancy 
minus HALE) increased from 1990 to 2016, indicating 
an absolute expansion of morbidity. YLL rates have 
fallen more rapidly than YLD rates so that non­fatal 
health loss as a proportion of DALYs has grown from 
1990 to 2016. This progress has been driven by marked 
reductions in DALYs due to CMNN causes and, to a 
lesser extent, by declines in age­standardised NCD and 
injury DALYs. Population growth in the past 27 years 
(from 5·27 billion to 7·39 billion) has resulted in a 
significant increase in total DALYs due to NCDs, coupled 
with a high total DALY burden in 2016, thus leading to 
an overall increasing toll on health systems.22,23 GBD 
2016 continues to unequivocally show an absolute 
Figure 4: Ratios of all-age DALY counts from NCDs to those from CMNN diseases by SDI quintile, GBD super-region, and region, for males and females separately, for 1990, 1995, 2000, 2006, 
2010, and 2016
Each point represents the ratio of DALYs from NCDs to those from CMNN diseases for each GBD region in a given year by sex. Ratios of more than 1·00 represent a greater number of DALYs from NCDs 
than from CMNN diseases. CMNN=communicable, maternal, neonatal, and nutritional. DALY=disability-adjusted life-year. GBD=Global Burden of Disease. NCDs=non-communicable diseases. 
SDI=Socio-demographic Index.
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Figure 5: Expected relationship between age-standardised YLL and YLD rates (per 100 000 people) and SDI (A) and all-age YLL and YLD rates (per 100 000 people) and SDI (B) for 21 Level 2 causes
These stacked curves represent the average relationship between SDI and YLL and YLD rates for each cause observed across all geographies over the time period 1990–2016. In each figure, the y axis 
goes from lowest SDI to highest SDI. The left side shows rates for YLLs on a reflected axis and the right side shows rates for YLDs; higher rates are further from the midline in each direction. Differences 
in patterns between (A) and (B) is the effect of shifts in population age structure in relation to SDI. DALY=disability-adjusted life-year. SDI=Socio-demographic Index. YLDs=years lived with disability. 
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Figure 6: Proportion of all-age DALY counts due to years lived with disability for all ages and both sexes combined for 1990 (A) and 2016 (B)
Locations are colour-coded in terms of the magnitude of the ratio. ATG=Antigua and Barbuda. DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. LCA=Saint Lucia. 
TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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expansion of morbidity4—that is, as life expectancy 
increases across a population, the absolute amount of 
functional health loss increases—but GBD 2016 also 
shows a relative compression of morbidity—that is, the 
proportion of total life spent ill per person decreases 
with increasing SDI.24 Substantial opportunities re­
main for innovation in human resources for health, 
development assistance for health, and targeted health 
policies to alleviate causes of old­age disability and 
transform the experience of later life for billions 
of people.25
From 1990 to 2016, life expectancy, HALE, and years 
lived with functional health loss all increased as 
populations moved through the SDI quintiles. These 
quintiles reflect in a geographical cross section of the 
world what is seen through time during the 
epidemiological transition. The rapid decrease in burden 
from CMNN diseases from low to high SDI quintile was 
most substantial. NCDs and injuries were also seen to 
decline, but at much more modest rates. Declines in 
fertility, increases in education, and increases in income 
per person (the triad of inputs into the SDI composite), 
were tightly coupled with population­based HALE 
outcomes.26 This finding suggests that the wide agendas 
of these three social determinants of health have roles 
within discussions of overall health system strengthening. 
Further dissection of the results clearly shows that a 
substantial impact has been made on the global burden 
of YLLs. A much more modest effect, however, has been 
made on the burden of large causes of YLDs at all levels 
of SDI. The contrast in this ratio is marked and illustrates 
another striking view of the epidemiological transition 
when looking at the proportion of DALYs due to YLDs 
globally. Although continued progress on reduction of 
YLLs prematurely is important, how to ameliorate the 
primary causes and underlying risks of YLDs globally 
should be reflected on (low back and neck pain, sense 
organ diseases, and skin diseases) to decrease the time 
that ageing populations live with functional health loss 
across the SDI spectrum. This persisting burden of 
morbidity highlights the importance, both in terms of 
relief of suffering and prevention of health­care costs, of 
placement of emphasis on prevention of disabling illness 
and mitigation of the ill effects of the disabling conditions 
that do occur.
Cross-cutting themes
The concept of the grand convergence—that levels of 
under­5 and maternal mortality, as well as selected 
infectious diseases, would converge across SDI quintiles 
within a generation—was promoted in the Lancet 
Commission on investing in health27 and discussed in the 
Figure 7: Ratio of observed to expected age-standardised DALY rates (per 100 000) on the basis of SDI alone for both sexes combined in 2016
Ratios are colour-coded in terms of the magnitude of differences between observed and expected age-standardised DALY rates. Blues indicate much lower observed DALY levels than expected on the 
basis of SDI, whereas reds reflect observed DALYs that far exceed expected levels given SDI. ATG=Antigua and Barbuda. DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. 
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GBD 2015 results.4 The conclusion that DALY convergence 
is likely to be accelerated by escalating increases in SDI 
remains valid. We have looked a step further in GBD 2016 
and highlighted countries that have most improved and 
showed the largest declines in their DALY performance 
relative to that expected on the basis of their SDI.
The pace and efficiency of a country’s transition 
through the SDI quintiles and the concurrent improve­
ments in population summary health metrics is by no 
means inevitable, however, and analysis derived from 
the ratio of observed to expected DALYs on the basis of 
SDI has been informative. The exemplars were 
Nicaragua, Costa Rica, the Maldives, Peru, and Israel, 
which had the lowest levels of age­standardised DALYs 
relative to the levels expected on the basis of SDI in 
2016. The appendix (pp 63–66) contains a full list of 
exemplars. These countries considerably outperformed 
health expectations relative to their development status. 
Conversely, Lesotho, Swaziland, South Africa, Fiji, and 
Botswana had the highest levels of age­standardised 
DALYs relative to those expected, reflecting a need for 
additional attention and examination of the reasons for 
these discrepancies. Lesotho had the highest ratio of 
age­standardised DALYs relative to that expected, which 
indicates poor performance in terms of health outcomes 
for mortality and morbidity relative to their SDI status.
The reasons for the success in health outcomes of the 
five exemplars merit in­depth analyses. Conversely, with 
the exception of Fiji (which is heavily impacted by the 
high levels of diabetes seen throughout Oceania), the 
poor performers in 2016 were clearly those that were 
most devastated by the continuing HIV/AIDS epidemic 
and, although progress has been made in South Africa, 
Swaziland, Zimbabwe, and Lesotho are still dis­
proportionately affected. Many different locations within 
the top ten exemplars and ten poor performers would 
make excellent case studies to assess the reasons for 
their relative rankings, particularly given the different 
health challenges and successes for each nation.
By highlighting exemplars and poor performers across 
the SDI quintiles, we have seen that the underlying 
influences that have contributed to the relative successes 
and failures of nations are substantially heterogeneous. A 
clear corollary is that the policy implications for reform 
will not be the same between quintiles. Nation­by­nation 
complexity in how countries progress through the SDI 
continuum and how population health summaries track 
is clearly too voluminous to document in this study by 































































































































































































































































0·0–0·64 0·64–0·81 0·81–0·97 0·97–1·07 1·07–1·18 1·18–1·37 1·37–1·71 1·71–2·77 ≥2·77
Figure 8: Leading ten causes of all-age DALYs with the ratio of observed to expected DALYs on the basis of Socio-demographic Index in 2016, by location
The ratio of observed to expected DALYs on the basis of Socio-demographic Index is provided in brackets for each cause and cells are colour-coded by ratio ranges (calculated to place a roughly equal 
number of cells into each bin). Shades of blue represent much lower observed DALY levels than expected on the basis of Socio-demographic Index, whereas red shows observed DALYs that exceed 
expected levels. Alcohol=alcohol use disorders. Alzheimer’s=Alzheimer’s disease and other dementias. Anxiety=anxiety disorders. Back+Neck=low back and neck pain. Cirr alc=cirrhosis due to alcohol 
use. Cirr HepC=cirrhosis due to hepatitis C. CKD=chronic kidney disease. CMP=cardiomyopathy and myocarditis. Colorect C=colon and rectum cancer. Conflict Terror=conflict and terrorism. 
Congenital=congenital anomalies. COPD=chronic obstructive pulmonary disease. Depression=depressive disorders. Diabetes=diabetes mellitus. Diarrhoea=diarrhoeal diseases. DR Congo=Democratic 
Republic of the Congo. Drugs=drug use disorders. HIV=HIV/AIDS. HTN HD=hypertensive heart disease. IHD=ischaemic heart disease. Iron=iron-deficiency anaemia. Liver C=liver cancer. LRI=lower 
respiratory infections. Lung C=lung, bronchus, and trachea cancers. NN Enceph=neonatal encephalopathy due to birth asphyxia and trauma. NN Preterm=neonatal preterm birth complications. 
NN Sepsis=neonatal sepsis and other neonatal infections. Oth Cardio=other cardiovascular and circulatory diseases. Oth MSK=other musculoskeletal disorders. Oth NN=Other neonatal disorders. 
PEM=protein-energy malnutrition. Prostate C=prostate cancer. Road Inj=road injuries. Sense=sense organ diseases. Skin=skin and subcutaneous diseases. STD=sexually transmitted diseases excluding 
HIV. Stomach C=stomach cancer. Stroke=Cerebrovascular disease. TB=tuberculosis. Violence=interpersonal violence. 
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nation, but we hope that the results of this study will 
spawn a plethora of derivative and policy­relevant research.
We have highlighted key exemplar nations and those 
whose progress could be improved, but there are clearly 
more general lessons that can be learned from the 
epidemiological transition across all causes and 
locations. The collection of London Declaration NTDs, 
along with malaria28 and HIV, all show how effective 
domestic and international collaborations in fighting of 
specific infectious diseases can be. Whether or not these 
collaborations provide evidence of health­care improve­
ments in one area, whether or not the benefits cascade, 
and whether or not non­health­specific interventions, 
such as poverty alleviation, education,29 and family 
planning, are having synergistic effects are hard to 
differentiate,28,30 but a host of online tools exist that 
enable national experts to examine performance of and 
changes in the leading causes of disease burden, 
compare them with peers, and objectively assess what 
can be improved.
Since the concept of the DALY was introduced two 
decades ago,31 it has become a key metric for monitoring 
of population health and prioritisation within health 
sectors.32–39 The following are examples of policy makers, 
funders, or foundations that use DALYs in decision 
making: WHO, the World Bank, the National Institutes 
of Health, the US Centers for Disease Control and 
Prevention, the Bill & Melinda Gates Foundation, Gavi, 
the US President’s Emergency Plan for AIDS Relief, the 
Global Fund, and the Wellcome Trust, as well as the 
Chinese Politburo, the National Institute for Health and 
Care Excellence, Indonesia Bappenas, and Public Health 
England at the national level.
Comparison of GBD 2016 with other global estimates 
and GBD 2015
The GBD study is the only source of comprehensive 
quantification of population health summary measures, 
including YLLs, YLDs, DALYs, and HALE. Specific 
efforts that are relevant to policy makers are being made 
to estimate burden within other organisations. Since 
GBD 2015, most organisations that we assessed have not 
produced updated estimates for DALYs or HALE. The 
exception to this is WHO, which has released updated 
Global Health Estimates for DALYs and HALE for 
183 countries from 2000 to 2015.40 These estimates draw 
heavily on the GBD 2015 results, with revisions to the 
all­cause mortality envelope40,41 as detailed in the GBD 
2016 cause­specific mortality publication10 and to selected 
cause­specific disability weights and severity distrib­
utions for YLDs.42 WHO­adjusted disability weights for 
various causes are further detailed in the WHO Global 
Health Estimates Technical Paper.41
Disease-specific considerations
The SDI transition was prominent for many CMNN 
conditions, especially diarrhoea, lower respiratory 
infection, HIV after 2005 (the year of the global peak), 
maternal disorders, and vaccine­preventable diseases 
like measles, tetanus, diphtheria, and pertussis. 
Focused programmes with community­wide targeting 
of health interventions—such as access to antenatal 
care,43,44 vaccination, malaria vector control (insecticide­
treated bednets and indoor residual spraying),45 and 
artemisinin combination therapies,46 water and 
sanitation efforts,47 and ART and prevention of mother­
to­child transmission of HIV30,48,49—are potentially 
responsible for DALY reductions in these conditions.50 
Further scale­up and maintenance of these interventions 
should continue, including a transition from non­
governmental organ isations to local ownership and 
financing. Corre sponding improvements in health 
system functions related to survival of mothers and 
their children have not occurred,51 shown by the 
comparatively slow improvement in DALYs due to 
maternal and neonatal disorders compared with other 
CMNN causes and the growing burden of congenital 
birth defects, haemo globinopathies and haemolytic 
anaemias, and sudden infant death syndrome, espec­
ially in the under­5 age group. Early detection of 
complications of pregnancy like micronutrient def­
iciencies, hypertensive disorders of pregnancy, preg­
nancy­transmitted and sexually trans mitted infec tions, 
and congenital birth defects can help identify the 
pregnant women and newborns at highest risk, help 
ensure that appropriate curative treatments are 
administered, and put the females and newborns in a 
position to receive timely perinatal care when it is 
needed. Newborn screening for congenital birth defects 
and haemoglobinopathies can, at the very least, identify 
children with these conditions and facilitate maternal 
education about the importance of presentation for care 
early when a mother’s child gets sick. Delays in seeking 
care can have deadly consequences, particularly for 
children with acute conditions. Education of mothers 
and fathers, especially first­time parents, about how to 
best care for their babies can help reduce avoidable 
injuries and deaths. At the same time, stark increases 
in neonatal sepsis DALYs, in which nosocomial 
infections of the newborn are included, highlight the 
crucial importance of being vigilant in infection control 
within hospitals and clinics.
This iteration of GBD estimated diseases and injuries for 
5 year age groups older than 80 years for the first time: 
80–84 years, 85–89 years, 90–94 years, and 95 years and 
older. This addition has provided a clearer picture than 
from previous GBD publications of the burden of disease 
in ageing populations, who are disproportionately affected 
by dementias and other NCDs compared with younger age 
groups. Ageing populations have increased substantially 
in size since 1990. As a result of this population shift and 
the epidemiological transition (which increases the pro­
portion of burden of disease due to NCDs), age groups 
older than 80 years had increases in all­age DALYs between 
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1990 and 2016, with increases across all SDI quintiles. The 
proportion due to NCDs also increased. Therefore, 
research into these age groups and the diseases that 
continue to affect them over time should be prioritised.
Tuberculosis
We made important changes to the modelling strategy for 
tuberculosis in GBD 2016. For fatal tuberculosis, we first 
modelled the prevalence of active disease and latent 
infection, which we then used as covariates for the Cause 
of Death Ensemble model. For non­fatal tuberculosis, we 
strengthened our statistical triangulation approach, which 
enforces consistency between data for different parameters 
by modelling tuberculosis incidence, prevalence, and 
mortality among those with latent infection. Application 
of MIRs estimated on the basis of SDI to better reflect 
incidence in low­income and middle­income countries 
has also enhanced consistency between fatal and non­fatal 
estimates of tuberculosis. All of these changes have 
resulted in global tuberculosis DALYs that are 15% higher 
than in GBD 2015 for the year 2010, with prominent 
increases occurring in several African countries, including 
Uganda, the Central African Republic, and Zambia.
HIV/AIDS
A major HIV methods change for GBD 2016 was the 
distribution of ART coverage by age, sex, and CD4­
positive cell count. We used two AIDS Indicator 
Surveys52,53 to predict the age­sex­CD4 cell distribution of 
ART coverage and applied the distributions to the input 
counts of people receiving ART in our HIV estimation 
model. This method shifted the coverage distribution to 
groups with higher CD4 cell counts, as was seen in the 
data. All of these changes have resulted in higher global 
HIV/AIDS DALYs than in GBD 2015 for the year 2010, 
with the most prominent increases occurring in several 
African countries, including South Africa, Botswana, 
Lesotho, and Swaziland. We have also systematically 
updated other key input parameters to the HIV/AIDS 
estimation process, such as the on­ART mortality rate 
and other demographic inputs, including HIV­free 
mortality.
Lower respiratory infection and diarrhoea
Total lower respiratory infection (increased by 0·701%) 
and diarrhoeal disease (increased by 15·5%) DALYs 
increased compared with GBD 2015 estimates for the 
year 2010. Like most CMNN causes, the lower 
respiratory infection and diarrhoeal disease DALY 
burden is due primarily to YLLs; more than 90% of 
global DALYs are from these causes. Several changes 
have been made to the under­5 mortality models that 
have large impacts on the DALY totals for these causes. 
We added several new model covariates on the basis of 
risk factors associated with lower respiratory infections 
and diarrhoeal diseases, including childhood stunting 
and suboptimal breastfeeding. Additionally, because of 
India’s large population size and disease burden, its 
Sample Registration System data changed the 
magnitude of YLLs. Inclusion of diarrhoeal diseases as 
a fatal discontinuity in YLL estimation also affected the 
overall estimation for GBD 2016. Overall, the YLLs due 
to lower respiratory infections decreased slightly (by 
0·626%) for the year 2010 from GBD 2015 to GBD 2016 
and those due to diarrhoeal diseases increased (by 
14·3%). We believe that these modelling changes 
improved under­5 mortality estimates for lower 
respiratory infections and diarrhoea. Although 
responsible for a smaller contribution to DALYs than 
cause of death models, the non­fatal models of lower 
respiratory infections and diarrhoea included new data 
sources and processing. An example is that we now 
account for seasonality from the population­
representative surveys that provide most prevalence 
data from sub­Saharan Africa and south Asia in the 
lower respiratory infection and diarrhoeal disease 
models. Another major update is a change in the 
estimated mean duration of illness on the basis of a set 
of updated systematic reviews. The duration of diarrhoea 
remained nearly the same as in GBD 2015, but that of 
lower respiratory infection decreased by about 20% 
compared with GBD 2015.
Malaria
Refinements to the methodological approach and 
addition of substantially more data than in GBD 2015 
have led to changes in estimates of both malaria 
mortality and morbidity estimates in the GBD 2016 
iteration, with resulting changes in DALYs. Globally, 
predicted trends in malaria were similar to GBD 2015, 
rising to a peak in 2005 before steadily declining. Overall 
malaria DALYs are lower in GBD 2016 than in GBD 2015, 
reflecting mainly lower estimates outside of Africa and 
particularly for India. Outside of Africa, and for lower­
burden countries within Africa, estimates were informed 
for the first time by extensive subnational case­reporting 
data from routine surveillance systems. These were 
subsequently adjusted to account for under­reporting, 
misdiagnosis, and incompleteness, and then entered 
into a spatiotemporal geostatistical model to infer 
continuous surfaces of incidence rate before re­
aggregating them to national and subnational totals. 
This approach led to notable reductions in estimated 
cases, YLDs, and DALYs in India, Myanmar, Indonesia, 
and Pakistan. In high­burden countries in sub­Saharan 
Africa, where the methods remained similar to GBD 
2015, changes were relatively modest and reflected the 
inclusion of newly available cross­sectional parasite rate 
surveys or updates to data for malaria intervention 
coverage in recent years.
London Declaration diseases
The London Declaration was established in 2012 as a 
partnership of pharmaceutical companies, private 
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foundations, and global health organisations, com mitted 
to providing resources and expertise for controlling, 
eliminating, or eradicating ten NTDs: human African 
trypanosomiasis, Chagas disease, Guinea worm disease, 
leprosy, lymphatic filariasis, oncho cerciasis, schistoso­
miasis, soil­transmitted hel minths, blinding trachoma, 
and visceral leishmaniasis.54 With this year’s addition of 
Guinea worm disease to the GBD cause list, we now 
estimate DALYs for all ten of the London Declaration 
diseases and GBD estimates can, therefore, offer insight 
into progress. We estimate that total DALYs from the 
London Declaration NTDs have declined by 21·1% from 
11·4 million (95% UI 6·8 million to 18·5 million) DALYs 
in 2010 before the London Declaration in 2012 to 
9·0 million (5·3 million to 14·5 million) in 2016. 
Moreover, we find that DALY rates have declined for all 
ten of the London Declaration NTDs between 1990 and 
2016, with the largest declines occurring for Guinea 
worm disease, reflecting the particular effectiveness of 
the Guinea worm eradication initiative,55 and for human 
African trypanosomiasis.56
Zika virus disease 
The appearance of Zika virus cases in the Americas in 
2015, along with the reported associations between Zika 
virus infection and microcephaly and Guillain­Barré 
syndrome, led WHO to declare Zika virus a Public Health 
Emergency of International Concern in February 2016.57–59 
We estimated Zika virus disease for GBD 2016 in 
response to this heightened global concern and interest. 
We estimated four non­fatal outcomes of Zika virus 
infection: asympto matic infection, symptomatic infec­
tion, Guillain­Barré syndrome caused by Zika virus 
infection, and congenital Zika syndrome. Despite the 
high incidence observed in the Americas in 2016 and 
understandable public concern, especially surrounding 
congenital Zika syndrome, we estimate that less than 
0·01% of Zika virus infections result in Guillain­Barré 
syndrome, congenital Zika syndrome, or death. We 
estimate that 7·60 million (95% UI 5·70 million to 
10·7 million) infections occurred in 2016, resulting in 
2·70 million symptomatic Zika virus cases, 1880 cases 
of Zika­attributable Guillain­Barré syndrome, and 
2400 congenital Zika syndrome births.8 Our estimate for 
congenital Zika syndrome is in line with official reports 
from the Pan American Health Organization of circa 
2500 congenital Zika syndrome births.60 However, those 
born with congenital Zika syndrome will have future 
disability.
Injuries
Global DALYs due to injuries generally contributed to a 
lower proportion of total burden than did those due to 
CMNN diseases and NCDs, and remained relatively 
stable as a proportion of total DALYs over time. Exam­
ination of these trends by SDI quintile, region, and 
cause of injury reveals much more variable patterns 
than the global pattern, which are potentially related to 
a confluence of demographic changes, policy adoption 
and enforcement, access to high­quality trauma care, 
and political stability. Among high­SDI and high­
middle­SDI countries, all­age DALYs due to road 
injuries have substantially declined since 1990, while 
DALYs due to road injuries in low­middle­SDI and low­
SDI countries have risen, a trend that is particularly 
evident in recent years. By contrast, DALYs from 
drowning markedly declined among middle­SDI and 
low­middle­SDI countries. Disease burden from falls 
rose across the development spectrum, a trend prim­
arily driven by population growth and ageing. Finally, 
the consequences of ongoing conflict, particularly in 
north Africa and the Middle East, and interpersonal 
violence, particularly in Latin America, on population 
health cannot be overlooked.61 Fatalities due to such 
conflict and violence have resulted in stagnated or 
decreasing life expectancy in many of these countries,7,62 
and for those who survive, the long­term effects of such 
injuries could easily result in impaired movement 
and functioning, heightened risk of other disorders 
(eg, musculoskeletal conditions), and mental health 
challenges for an extended period after the end of 
the conflict.
Cerebrovascular disease
For GBD 2016, we modelled each stroke subtype 
independently to produce more reliable ratios of ischaemic 
to haemorrhagic stroke than for GBD 2015 and better 
match our independent estimation of subtype­specific 
stroke mortality. We avoided undercounting of stroke by 
reclassifying hospital admissions and deaths ascribed to 
unspecified stroke. Despite this method, haemorrhagic 
stroke remains a heterogeneous category that includes 
neonatal intraventricular haemorrhage and all other non­
traumatic intracranial bleeding. These deaths in children 
younger than 5 years result in many more YLLs, and 
therefore many more DALYs, than from ischaemic stroke. 
Consistent with population­based and multinational 
studies of stroke subtype, GBD estimates higher incidence 
but much lower case fatality and YLLs due to ischaemic 
stroke among adults than due to haemorrhagic stroke.63 
This pattern appears true even for locations where this 
pattern was not previously thought to be the case, such as 
in China.64 Future estimates can be improved by 
production of separate estimates of non­traumatic 
subarachnoid haemorrhage and paediatric stroke.
Mental and substance use disorders
Throughout multiple iterations of GBD, mental and 
substance use disorders have consistently been shown as 
the leading causes of YLDs worldwide, with burden 
present in both sexes across the lifespan. They are also 
strongly associated with premature mortality, although 
this association is not reflected in GBD YLL estimates for 
mental disorders as they are rarely coded as the direct 
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cause of death. Nevertheless, they contribute a substantial 
number of DALYs and this large contribution to burden 
has remained constant across time in all countries, 
including those with high or substantially improving SDI. 
Treatment rates remain very low65–67 and, even in high­
income countries where treatment coverage has increased, 
the prevalence of the most common disorders has not 
changed.68 To reduce the burden of these disorders, 
improved treatment coverage needs to include a focus on 
the quality of the intervention delivered. Additionally, 
identification and quantification of modifiable risk factors 
for mental and substance use disorders are vital for 
development of effective prevention strategies and are an 
area noted for expansion in future iterations of GBD.
Diabetes
We made several important improvements to the process 
of estimation of diabetes prevalence, including use of 
more data sources than GBD 2015 and development of a 
novel approach to standardise the definition of diabetes 
across different sources. In our assessment of diagnostic 
criteria for diabetes across different surveys, we 
identified more than 50 different definitions for diabetes 
based on various biomarkers (eg, fasting plasma glucose 
concentration, oral glucose tolerance test result, and 
glycated haemoglobin A1c concentration) and different 
levels of each biomarker. To standardise the definition of 
diabetes, we mostly focused on the surveys that had 
included fasting plasma glucose concentration as a 
diagnostic criterion and developed an ensemble model 
to characterise the distribution of fasting plasma glucose 
concentration at the population level in each age and sex 
group. Then, we used the fasting plasma glucose 
concentration distribution to convert various definitions 
of diabetes into the standard case definition. Using the 
ensemble model, we also estimated the prevalence of 
diabetes on the basis of the mean fasting plasma glucose 
concentration in places for which we only had data for 
mean fasting plasma glucose concentration. These 
changes allowed us to be more consistent than in GBD 
2015 in our estimation of the prevalence of diabetes 
across countries and over time. As a result, our estimates 
of the prevalence of diabetes globally and in most 
regions are slightly lower than those reported in GBD 
2015. The strong relationship between SDI and 
diabetes remained, mirroring global rises in overweight 
and obesity.69
Cancer
DALYs for cancer have changed compared with 
GBD 2015; this change is predominantly due to lower 
YLD estimates for GBD 2016 than for GBD 2015. These 
improvements stem from adjustments made in the 
modelling of MIRs to better reflect differences in MIR 
based on SDI in data­sparse locations than in GBD 2015. 
In addition to stricter inclusion criteria for data used in 
the MIR modelling than in GBD 2015, we changed the 
modelling approach and used the most parsimonious 
model with just SDI as a predictor of MIR.8 MIRs are 
used to estimate cancer incidence and prevalence from 
GBD cancer mortality estimates and therefore directly 
determine YLDs. Until cancer registry incidence data 
and accurate mortality statistics are widely available, 
validation of MIR is difficult in countries that lack these 
data sources. The Global Initiative for Cancer Registry 
Development and expansion of civil registration systems 
are therefore crucial to further improve estimation of 
cancer burden.
Future directions
Challenging data gaps exist in the severity distributions 
across sequelae for most diseases in the YLD literature. 
Most data sources for severity are from high­income 
countries, which probably leads to an underestimation of 
YLDs in low­income and middle­income countries where 
the severity of presentation of non­fatal illnesses might be 
worse than in high­income countries, frequently as a result 
of late diagnosis and underdiagnosis. Improvements can 
be made if disease­specific research focuses on routine use 
of a single established measure of severity in surveys and 
patient populations and if countries are able to link survey 
data to a general health assessment instrument, along with 
improvements in early diagnosis and treatment procedures 
before illnesses progress to high­severity presentations. 
Although uncertainty and sample variance will persist at 
various levels, gaining of greater geographical information 
on severity of diseases than at present will increase the 
accuracy of GBD models.
Potential is clearly huge for exploration of this work in 
relation to development assistance for health,70,71 as the 
connection between health financing and outcomes needs 
better understanding than at present. Improved under­
standing will probably help identify the reasons why 
certain countries have such an impressive record, whereas 
others are so ineffective with the resources that they have 
available, at all levels of SDI. More precise measurement of 
health burden than at present, across countries and at the 
subnational level, could be tied to health services financing 
and delivery to identify systematic associations and causal 
relationships. Additionally, risk factor data, health outcome 
data, health financing data, and other socioeconomic 
indicators can be combined to measure and assess health 
system performance. Furthermore, a core focus moving 
forward with GBD is to progressively increase the spatial 
resolution at which we implement estimations to help 
realise aspirations in precision public health.72 A key goal 
of a geographically refined DALY, at 5 × 5 km spatial 
resolution—starting with some key CMNN causes and 
under­5 mortality—is part of a long­term aspiration.73
Finally, upcoming GBD work will focus on exploration 
of future health scenarios, examining the likely burden 
of disease under different possible trajectories of 
independent drivers of health. This framework will 
capture the complex past trends and interdependent 
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relationships in socioeconomic development, risk 
factors, interventions, morbidity, mortality, and 
population to both estimate the likely future burden of 
disease and enable comparison between scenarios based 
on different sets of assumptions. For instance, it can be 
used to analyse the likely effect of the introduction and 
scale­up of a new type of vaccination or different trends 
in funding for ART for HIV/AIDS. Extension of this 
work through to DALY and HALE analyses is also part of 
these future plans.
To look at cause­deleted HALE would also be valuable so 
that we could understand the remaining DALY burden in 
the absence of diseases and injuries that might be highly 
amenable to preventive or curative measures. Compelling 
examples would include HIV, vaccine­preventable and 
malnutrition­related diseases, a subset of NCDs that are 
particularly amenable to health­care or preventive 
measures (eg, tobacco­related or alcohol­related or some 
congenital birth defects), and injuries (eg, firearms or 
transport injuries). This approach would not be fully 
counterfactual, but would be a first and more rigorous way 
of showing what conditions contributed to the changes in 
HALE from 1990 (or 2006) to 2016 than was possible in 
this study.
Limitations
Despite our continued methodological advancements and 
data enrichments, this study has limitations. First, all 
limitations documented in the elements of the GBD 
estimation process that allow for DALY and HALE 
estimation2–4,12 will contribute to uncertainty in these 
summary measures. Second, these summary measures 
will also be influenced by data availability. Time lags in the 
reporting of health information by national authorities 
and thus their subsequent incorporation into the GBD 
estimation mean that some of the most recent changes in 
health states will not be captured. Relatedly, data 
deficiencies from populations in conflict zones (eg, 
Syria, Iraq, Yemen, South Sudan, and Afghanistan), 
autonomous subnational regions, and certain non­
geographically based subpopulations (ie, migrants, 
refugees, and some indigenous people) limit the precision 
of some of our estimated levels and trends of disease 
burden.74 Third, the relationship between DALYs, HALE, 
and SDI, although explanatory, cannot be viewed as 
causal. Fourth, a non­trivial assumption of the analyses is 
the independence of the uncertainty calculated for YLLs 
and YLDs. Because of the link between death and 
prevalence, a positive correlation probably exists between 
these uncertainties that we do not capture. As such, we 
probably underestimate the aggregated uncertainty for 
DALYs, although the primary source of uncertainty for 
DALYs comes from uncertainty in disability weights, 
which are unaffected by this limitation. In future iterations 
of GBD, this potential correlation will be explored 
using copula, a statistical method that models the 
dependence structure among multiple independent 
marginal probability distributions to estimate correlation 
between them.75
Conclusion
Many improvements have been made to GBD 2016 to 
allow for a clearer and more nuanced picture of the 
changing picture of global health than in GBD 2015. 
Among these improvements are inclusion of new studies 
and subnational data (notably in India) and many 
substantial improvements to modelling and analyses. 
Prominent results of these changes include higher global 
DALY estimates for tuberculosis, HIV/AIDS, lower 
respiratory infection, and diarrhoeal disease than in GBD 
2015. We have for the first time discussed our DALY 
exemplars, countries with the lowest ratio of observed to 
expected DALYs, as well as our poor performers, those 
with the largest ratio of observed to expected DALYs. 
These exemplars and poor performers suggest a need to 
learn lessons from those with clear health gains and 
implement system­based strategies for those struggling. 
This analysis and increasingly more detailed results will 
allow for more informed public policy and health 
financing decisions as the world faces an absolute 
expansion of morbidity.
Globally, individuals could expect to live substantially 
longer lives in 2016 than they could in 1990. This 
improvement was due to a rapid decline in YLLs and 
more modest age­standardised declines in YLDs, leading 
to lower age­standardised DALY rates across the entire 
socioeconomic development spectrum in 2016 than in 
1990, with a decrease of approximately a third for all 
causes. At the same time, populations can expect to spend 
more time with functional health loss due to absolute 
morbidity expansion than previously. Such improvements 
have been accompanied by rapid population growth and 
ageing and, against the backdrop of the epidemiological 
transition, have resulted in the paradox of a total 
expansion in DALY burden and thus an ever­increasing 
demand on health systems, domestic health financing, 
development assistance for health, and associated global 
health organisations. This increasing demand on health 
systems is ubiquitous across time, location, GBD region, 
and SDI, posing a huge opportunity for health­care 
innovators in prevention and treatment for morbidity 
reduction. Our analysis of exemplars and poor performers 
is also indicative of various practices that can hasten or 
slow the epidemiological transition and warrant deep 
investigation.
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